Universal Health Services (UHS) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	UHS
Entity Registrant Name	UNIVERSAL HEALTH SERVICES INC
Entity Central Index Key	0000352915
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	1-10765
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2077891
Entity Address, Address Line One	UNIVERSAL CORPORATE CENTER
Entity Address, Address Line Two	367 SOUTH GULPH ROAD
Entity Address, City or Town	KING OF PRUSSIA
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19406
City Area Code	610
Local Phone Number	768-3300
Entity Interactive Data Current	Yes
Security Exchange Name	NYSE
Title of 12(b) Security	Class B Common Stock, $0.01 par value
Document Quarterly Report	true
Document Transition Report	false
Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		6,577,100
Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		77,700,358
Class C
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		661,688
Class D
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		18,411

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net revenues	$ 2,729,754	$ 2,855,168	$ 5,559,421	$ 5,659,559
Operating charges:
Salaries, wages and benefits	1,308,010	1,383,481	2,740,679	2,749,027
Other operating expenses	625,747	672,564	1,315,537	1,317,344
Supplies expense	283,572	305,857	601,399	613,320
Depreciation and amortization	126,208	121,168	250,602	241,208
Lease and rental expense	28,186	26,535	56,479	52,660
Operating Expenses, Total	2,371,723	2,509,605	4,964,696	4,973,559
Income from operations	358,031	345,563	594,725	686,000
Interest expense, net	25,473	42,487	61,824	82,127
Other (income) expense, net	(3,100)	(7,732)	6,460	(3,231)
Income before income taxes	335,658	310,808	526,441	607,104
Provision for income taxes	79,154	69,543	125,477	128,441
Net income	256,504	241,265	400,964	478,663
Less: Net income attributable to noncontrolling interests	4,575	2,945	6,998	6,175
Net income attributable to UHS	$ 251,929	$ 238,320	$ 393,966	$ 472,488
Basic earnings per share attributable to UHS	$ 2.97	$ 2.67	$ 4.60	$ 5.24
Diluted earnings per share attributable to UHS	$ 2.95	$ 2.66	$ 4.58	$ 5.23
Weighted average number of common shares - basic	84,632	89,136	85,422	89,956
Add: Other share equivalents	427	99	335	145
Weighted average number of common shares and equivalents - diluted	85,059	89,235	85,757	90,101

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 256,504	$ 241,265	$ 400,964	$ 478,663
Other comprehensive income (loss):
Unrealized derivative gains (losses) on cash flow hedges		(1,008)		(3,925)
Foreign currency translation adjustment	6,676	5,159	(32,525)	(9,103)
Other comprehensive income (loss) before tax	6,676	4,151	(32,525)	(13,028)
Income tax expense (benefit) related to items of other comprehensive income (loss)	898	1,616	(1,210)	(850)
Total other comprehensive income (loss), net of tax	5,778	2,535	(31,315)	(12,178)
Comprehensive income	262,282	243,800	369,649	466,485
Less: Comprehensive income attributable to noncontrolling interests	4,575	2,945	6,998	6,175
Comprehensive income attributable to UHS	$ 257,707	$ 240,855	$ 362,651	$ 460,310

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 539,622	$ 61,268
Accounts receivable, net	1,438,697	1,560,847
Supplies	167,626	159,889
Other current assets	150,842	133,930
Total current assets	2,296,787	1,915,934
Property and equipment	9,398,890	9,106,377
Less: accumulated depreciation	(4,294,341)	(4,089,679)
Property, plant and equipment, net, Total	5,104,549	5,016,698
Other assets:
Goodwill	3,836,020	3,869,760
Deferred income taxes	20,241	16,189
Right of use assets-operating leases	335,388	326,518
Deferred charges	6,390	6,373
Other	549,124	516,778
Total Assets	12,148,499	11,668,250
Current liabilities:
Current maturities of long-term debt	82,085	87,550
Accounts payable and other liabilities	1,371,698	1,272,374
Medicare accelerated payments and deferred governmental stimulus grants	477,099
Legal reserves	145,227	144,509
Operating lease liabilities	56,629	56,442
Federal and state taxes	126,431	2,515
Total current liabilities	2,259,169	1,563,390
Other noncurrent liabilities	374,616	329,932
Operating lease liabilities noncurrent	279,747	270,076
Long-term debt	3,449,940	3,896,577
Deferred income taxes	19,168	25,071
Redeemable noncontrolling interests	4,287	4,333
Equity:
UHS common stockholders’ equity	5,688,647	5,504,105
Noncontrolling interest	72,925	74,766
Total equity	5,761,572	5,578,871
Total Liabilities and Stockholders’ Equity	$ 12,148,499	$ 11,668,250

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Redeemable Noncontrolling Interest	Class A	Class B	Class C	Class D	Cumulative Dividends	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	UHS Common Stockholders' Equity	Noncontrolling Interest
Balance at Dec. 31, 2018	$ 5,465,793		$ 66	$ 841	$ 7	$ 0	$ (409,156)	$ 5,793,262	$ 4,242	$ 5,389,262	$ 76,531
Balance at Dec. 31, 2018		$ 4,292
Common Stock
Issued/(converted)	5,405			6				5,399		5,405
Repurchased	(478,072)			(37)				(478,035)		(478,072)
Restricted share-based compensation expense	3,659							3,659		3,659
Dividends paid	(17,953)						(17,953)			(17,953)
Stock option expense	30,478							30,478		30,478
Distributions to noncontrolling interests	(11,150)	(500)									(11,150)
Comprehensive income:
Net income to UHS / noncontrolling interests	478,469							472,488		472,488	5,981
Net income attributable to redeemable noncontrolling interest		194
Foreign currency translation adjustments, net of income tax	(9,181)								(9,181)	(9,181)
Unrealized derivative gains on cash flow hedges, net of income tax	(2,997)								(2,997)	(2,997)
Subtotal - comprehensive income	466,291							472,488	(12,178)	460,310	5,981
Subtotal attributable to redeemable noncontrolling interest		194
Balance at Jun. 30, 2019	5,464,451		66	810	7	0	(427,109)	5,827,251	(7,936)	5,393,089	71,362
Balance at Jun. 30, 2019		3,986
Balance at Mar. 31, 2019	5,552,311		66	837	7	0	(418,237)	5,910,213	(10,471)	5,482,415	69,896
Balance at Mar. 31, 2019		3,843
Common Stock
Issued/(converted)	2,679							2,679		2,679
Repurchased	(340,843)			(27)				(340,816)		(340,843)
Restricted share-based compensation expense	2,136							2,136		2,136
Dividends paid	(8,872)						(8,872)			(8,872)
Stock option expense	14,719							14,719		14,719
Distributions to noncontrolling interests	(1,336)										(1,336)
Comprehensive income:
Net income to UHS / noncontrolling interests	241,122							238,320		238,320	2,802
Net income attributable to redeemable noncontrolling interest		143
Foreign currency translation adjustments, net of income tax	3,308								3,308	3,308
Unrealized derivative gains on cash flow hedges, net of income tax	(773)								(773)	(773)
Subtotal - comprehensive income	243,657							238,320	2,535	240,855	2,802
Subtotal attributable to redeemable noncontrolling interest		143
Balance at Jun. 30, 2019	5,464,451		66	810	7	0	(427,109)	5,827,251	(7,936)	5,393,089	71,362
Balance at Jun. 30, 2019		3,986
Balance at Dec. 31, 2019	5,578,871		66	794	7	0	(462,159)	5,933,504	31,893	5,504,105	74,766
Balance at Dec. 31, 2019		4,333
Common Stock
Issued/(converted)	5,963			3				5,960		5,963
Repurchased	(200,054)			(20)				(200,034)		(200,054)
Restricted share-based compensation expense	4,749							4,749		4,749
Dividends paid	(17,344)						(17,344)			(17,344)
Stock option expense	28,577							28,577		28,577
Distributions to noncontrolling interests	(8,385)	(500)									(8,385)
Comprehensive income:
Net income to UHS / noncontrolling interests	400,510							393,966		393,966	6,544
Net income attributable to redeemable noncontrolling interest		454
Foreign currency translation adjustments, net of income tax	(31,315)								(31,315)	(31,315)
Subtotal - comprehensive income	369,195							393,966	(31,315)	362,651	6,544
Subtotal attributable to redeemable noncontrolling interest		454
Balance at Jun. 30, 2020	5,761,572		66	777	7	0	(479,503)	6,166,722	578	5,688,647	72,925
Balance at Jun. 30, 2020	4,000	4,287
Balance at Mar. 31, 2020	5,485,043		66	776	7	0	(479,503)	5,897,063	(5,200)	5,413,209	71,834
Balance at Mar. 31, 2020		3,953
Common Stock
Issued/(converted)	2,851			1				2,850		2,851
Repurchased	(762)							(762)		(762)
Restricted share-based compensation expense	2,394							2,394		2,394
Stock option expense	13,248							13,248		13,248
Distributions to noncontrolling interests	(3,151)										(3,151)
Comprehensive income:
Net income to UHS / noncontrolling interests	256,171							251,929		251,929	4,242
Net income attributable to redeemable noncontrolling interest		334
Foreign currency translation adjustments, net of income tax	5,778								5,778	5,778
Subtotal - comprehensive income	261,949							251,929	5,778	257,707	4,242
Subtotal attributable to redeemable noncontrolling interest		334
Balance at Jun. 30, 2020	5,761,572		$ 66	$ 777	$ 7	$ 0	$ (479,503)	$ 6,166,722	$ 578	$ 5,688,647	$ 72,925
Balance at Jun. 30, 2020	$ 4,000	$ 4,287

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities:
Net income	$ 400,964	$ 478,663
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation & amortization	250,602	241,208
Loss on sale of assets and businesses	2,161
Stock-based compensation expense	33,954	34,676
Changes in assets & liabilities, net of effects from acquisitions and dispositions:
Accounts receivable	131,294	(101,329)
Accrued interest	(2,191)	948
Accrued and deferred income taxes	116,707	(16,846)
Other working capital accounts	26,361	30,082
Medicare accelerated payments and deferred governmental stimulus grants	477,099
Other assets and deferred charges	5,095	(1,333)
Other	(7,659)	(1,209)
Accrued insurance expense, net of commercial premiums paid	81,016	51,819
Payments made in settlement of self-insurance claims	(64,034)	(44,115)
Net cash provided by operating activities	1,451,369	672,564
Cash Flows from Investing Activities:
Property and equipment additions, net of disposals	(354,610)	(323,920)
Proceeds received from sales of assets and businesses	6,440
Acquisition of businesses and property	(968)
Inflows from foreign exchange contracts that hedge our net U.K. investment	57,029	4,885
Costs incurred for purchase and implementation of information technology applications	(4,421)	(13,893)
Investment in, and advances to, joint ventures and other	(285)	(11,949)
Net cash used in investing activities	(296,815)	(344,877)
Cash Flows from Financing Activities:
Reduction of long-term debt	(459,332)	(28,617)
Additional borrowings	5,453	177,200
Repurchase of common shares	(200,054)	(494,649)
Dividends paid	(17,344)	(17,953)
Issuance of common stock	5,852	5,271
Profit distributions to noncontrolling interests	(8,885)	(11,650)
Net cash used in financing activities	(674,310)	(370,398)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(1,639)	(273)
Increase (decrease) in cash, cash equivalents and restricted cash	478,605	(42,984)
Cash, cash equivalents and restricted cash, beginning of period	105,667	199,685
Cash, cash equivalents and restricted cash, end of period	584,272	156,701
Supplemental Disclosures of Cash Flow Information:
Interest paid	61,802	78,623
Income taxes paid, net of refunds	14,394	145,404
Noncash purchases of property and equipment	80,031	71,923
Right-of-use assets obtained in exchange for lease obligations	$ 37,780	$ 359,329

General

General	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	(1) General This Quarterly Report on Form 10-Q is for the quarterly period ended June 30, 2020. In this Quarterly Report, “we,” “us,” “our” “UHS” and the “Company” refer to Universal Health Services, Inc. and its subsidiaries. The condensed consolidated interim financial statements include the accounts of our majority-owned subsidiaries and partnerships and limited liability companies controlled by us, or our subsidiaries, as managing general partner or managing member. The condensed consolidated interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments (consisting only of normal recurring adjustments) which, in our opinion, are necessary to fairly state results for the interim periods. Certain information and footnote disclosures normally included in audited consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements, significant accounting policies and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. In March, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the federal government declared COVID-19 a national emergency. Patient volumes at both our acute care and behavioral health care facilities were most significantly reduced in April. Our acute care and behavioral health facilities began experiencing gradual and continued improvement in patient volumes in May and June as various states eased stay-at-home restrictions and acute care hospitals were permitted to resume elective surgeries and procedures. However, many of our acute care and behavioral health facilities are located in states that began experiencing significant increases in COVID-19 infections in June and continuing through July and into early August. We believe that the adverse impact that COVID-19 will have on our future operations and financial results will depend upon many factors, most of which are beyond our capability to control or predict. Such factors include, but are not limited to, the scope and duration of stay-at-home policies and business closures and restrictions, government imposed or recommended suspensions of elective surgeries and procedures, continued declines in patient volumes for an indeterminable length of time, increases in the number of uninsured and underinsured patients as a result of higher sustained rates of unemployment, incremental expenses required for supplies and personal protective equipment, and changes in professional and general liability exposure. Because of these and other uncertainties, we cannot estimate the length or severity of the impact of COVID-19 on our business. Decreases in cash flows and results of operations may have an impact on the inputs and assumptions used in significant accounting estimates, including estimated implicit price concessions related to uninsured patient accounts, professional and general liability reserves, and potential impairments of goodwill and long-lived assets.

Relationship with Universal Hea

Relationship with Universal Health Realty Income Trust and Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Relationship with Universal Health Realty Income Trust and Related Party Transactions	(2) Relationship with Universal Health Realty Income Trust and Related Party Transactions Relationship with Universal Health Realty Income Trust: At June 30, 2020, we held approximately 5.7% of the outstanding shares of Universal Health Realty Income Trust (the “Trust”). We serve as Advisor to the Trust under an annually renewable advisory agreement, which is scheduled to expire on December 31 st In addition, certain of our officers and directors are also officers and/or directors of the Trust. Management believes that it has the ability to exercise significant influence over the Trust, therefore we account for our investment in the Trust using the equity method of accounting. Our pre-tax share of income from the Trust, which are included in other income, net, on the accompanying consolidated statements of income for each period were approximately $200,000 during each of the three-month periods ended June 30, 2020 and 2019, and approximately $500,000 during each of the six-month periods ended June 30, 2020 and 2019. We received dividends from the Trust amounting to $543,000 and $536,000 during the three month periods ended June 30, 2020 and 2019, respectively, and $1.1 million during each of the six-month periods ended June 30, 2020 and 2019. The carrying value of our investment in the Trust was approximately $5.9 million and $6.4 million at June 30, 2020 and December 31, 2019, respectively, and is included in other assets in the accompanying consolidated balance sheets. The market value of our investment in the Trust was $62.6 million at June 30, 2020 and $92.4 million at December 31, 2019, based on the closing price of the Trust’s stock on the respective dates. The Trust commenced operations in 1986 by purchasing certain properties from us and immediately leasing the properties back to our respective subsidiaries. Most of the leases were entered into at the time the Trust commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. Each lease also provided for additional or bonus rental, as discussed below. The base rents are paid monthly and the bonus rents are computed and paid on a quarterly basis, based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The leases with those subsidiaries are unconditionally guaranteed by us and are cross-defaulted with one another. Total rent expense under the operating leases on the three hospital facilities with the Trust was approximately $4 million during each of the three months ended June 30, 2020 and 2019, and approximately $8 million for each of the six-month periods ended June 30, 2020 and 2019. Pursuant to the terms of the three hospital leases with the Trust, we have the option to renew the leases at the lease terms described above and below by providing notice to the Trust at least 90 days prior to the termination of the then current term. We also have the right to purchase the respective leased hospitals at the end of the lease terms or any renewal terms at their appraised fair market value as well as purchase any or all of the three leased hospital properties at the appraised fair market value upon one month’s notice should a change of control of the Trust occur. In addition, we have rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. The table below details the renewal options and terms for each of our three acute care hospital facilities leased from the Trust: Hospital Name Annual Minimum Rent End of Lease Term Renewal Term (years) McAllen Medical Center $ 5,485,000 December, 2026 5(a) Wellington Regional Medical Center $ 3,030,000 December, 2021 10(b) Southwest Healthcare System, Inland Valley Campus $ 2,648,000 December, 2021 10(b) (a) We have one (b) We have two 5-year In addition, certain of our subsidiaries are tenants in several medical office buildings and two FEDs owned by the Trust or by limited liability companies in which the Trust holds 95% to 100% of the ownership interest. During the third quarter of 2019, the Trust commenced construction on a new 75,000 rentable square feet medical office building (“MOB”) that will be located on the campus of Texoma Medical Center, a hospital that is owned and operated by one of our subsidiaries. In connection with this MOB, a master flex lease has been executed between a wholly-owned subsidiary of ours and a Trust limited partnership that owns the MOB. Pursuant to the terms of this master flex lease, our subsidiary will master lease approximately 50% of the rentable square feet of the MOB, allocated to specific floors of the building, which could be reduced during the term if certain conditions are met, for a ten-year During the third quarter of 2019, a joint-venture agreement between us and a non-related third-party was finalized in connection with the development of a newly constructed behavioral health care facility located in Clive, Iowa. Pursuant to the terms of the agreement, we hold a majority ownership interest in the venture and will act as manager of the facility when completed and opened. This joint-venture also entered into an agreement with the Trust whereby a wholly-owned subsidiary of the Trust will construct the 108-bed behavioral health care hospital and, upon completion and issuance of the certificate of occupancy, the joint-venture will lease the facility from the Trust pursuant to a 20-year, triple net lease with five, 10-year renewal options. Construction of the approximately 80,000 square foot hospital, for which a wholly-owned subsidiary of ours will act as project manager for an aggregate fee of approximately $750,000, is expected to be completed in late 2020 or early 2021. The approximate cost of the project is estimated at $37.5 million and the initial annual rent is estimated at approximately $2.7 million. Other Related Party Transactions: In December, 2010, our Board of Directors approved the Company’s entering into supplemental life insurance plans and agreements on the lives of Alan B. Miller (our chief executive officer (“CEO”) and his wife. As a result of these agreements, as amended in October, 2016, based on actuarial tables and other assumptions, during the life expectancies of the insureds, we would pay approximately $28 million in premiums, and certain trusts owned by our CEO, would pay approximately $9 million in premiums. Based on the projected premiums mentioned above, and assuming the policies remain in effect until the death of the insureds, we will be entitled to receive death benefit proceeds of no less than approximately $37 million representing the $28 million of aggregate premiums paid by us as well as the $9 million of aggregate premiums paid by the trusts. In connection with these policies, we will pay/we paid approximately $1.1 million, net, in premium payments during each of the 2020 and 2019 years. In August, 2015, Marc D. Miller, our President and member of our Board of Directors, was appointed to the Board of Directors of Premier, Inc. (“Premier”), a healthcare performance improvement alliance. During 2013, we entered into a new group purchasing organization agreement (“GPO”) with Premier. In conjunction with the GPO agreement, we acquired a minority interest in Premier for a nominal amount. During the fourth quarter of 2013, in connection with the completion of an initial public offering of the stock of Premier, we received cash proceeds for the sale of a portion of our ownership interest in the GPO. Also in connection with this GPO agreement, we received shares of restricted stock of Premier which vest ratably over a seven-year A member of our Board of Directors and member of the Executive Committee and Finance Committee is a partner in Norton Rose Fulbright US LLP, a law firm engaged by us for a variety of legal services. The Board member and his law firm also provide personal legal services to our CEO and he acts as trustee of certain trusts for the benefit of our CEO and his family.

Other Noncurrent liabilities an

Other Noncurrent liabilities and Redeemable/Noncontrolling Interests	6 Months Ended
	Jun. 30, 2020
Noncontrolling Interest [Abstract]
Other Noncurrent liabilities and Redeemable/Noncontrolling Interests	(3) Other Noncurrent liabilities and Redeemable/Noncontrolling Interests Other noncurrent liabilities include the long-term portion of our professional and general liability, workers’ compensation reserves, pension and deferred compensation liabilities, and liabilities incurred in connection with split-dollar life insurance agreements on the lives of our chief executive officer and his wife. As of June 30, 2020, outside owners held noncontrolling, minority ownership interests of: (i) 20% in an acute care facility located in Washington, D.C.; (ii) approximately 11% in an acute care facility located in Texas; (iii) 20%, 30% and 20% in three behavioral health care facilities located in Pennsylvania, Ohio and Washington, respectively, and; (iv) approximately 5% in an acute care facility located in Nevada. The noncontrolling interest and redeemable noncontrolling interest balances of $73 million and $4 million, respectively, as of June 30, 2020, consist primarily of the third-party ownership interests in these hospitals. In connection with the two behavioral health care facilities located in Pennsylvania and Ohio, the minority ownership interests of which are reflected as redeemable noncontrolling interests on our Condensed Consolidated Balance Sheet, the outside owners have “put options” to put their entire ownership interest to us at any time. If exercised, the put option requires us to purchase the minority member’s interest at fair market value.

Treasury

Treasury	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Treasury	(4) Treasury Credit Facilities and Outstanding Debt Securities: On October 23, 2018, we entered into a Sixth Amendment (the “Sixth Amendment”) to our credit agreement dated as of November 15, 2010, as amended on March 15, 2011, September 21, 2012, May 16, 2013, August 7, 2014 and June 7, 2016, among UHS, as borrower, the several banks and other financial institutions from time to time parties thereto, as lenders, JPMorgan Chase Bank, N.A., as administrative agent, and the other agents party thereto (the “Senior Credit Agreement”). The Sixth Amendment became effective on October 23, 2018. The Sixth Amendment amended the Senior Credit Agreement to, among other things: (i) increased the aggregate amount of the revolving credit facility to $1 billion (increase of $200 million over the $800 million previous commitment); (ii) increased the aggregate amount of the tranche A term loan commitments to $2 billion (increase of approximately $290 million over the $1.71 billion of outstanding borrowings prior to the amendment), and; (iii) extended the maturity date of the revolving credit and tranche A term loan facilities to October 23, 2023 from August 7, 2019. On October 31, 2018, we added a seven-year tranche B term loan facility in the aggregate principal amount of $500 million pursuant to the Senior Credit Agreement. The tranche B term loan matures on October 31, 2025. We used the proceeds to repay borrowings under the revolving credit facility, the Securitization (as defined below), to redeem our $300 million, 3.75% Senior Notes that were scheduled to mature in 2019 and for general corporate purposes. As of June 30, 2020, we had no borrowings outstanding pursuant to our $1 billion revolving credit facility and we had $997 million of available borrowing capacity net of $3 million of outstanding letters of credit. Pursuant to the terms of the Sixth Amendment, the tranche A term loan, which had $1.925 billion of borrowings outstanding as of June 30, 2020, provides for eight installment payments of $12.5 million per quarter which commenced in March of 2019 and are scheduled to continue through December of 2020. Thereafter, payments of $25 million per quarter are scheduled, commencing in March of 2021 until maturity in October of 2023, when all outstanding amounts will be due. The tranche B term loan, which had $493 million of borrowings outstanding as of June 30, 2020, provides for installment payments of $1.25 million per quarter, which commenced on March 31, 2019 and are scheduled to continue until maturity in October of 2025, when all outstanding amounts will be due. Borrowings under the Senior Credit Agreement bear interest at our election at either (1) the ABR rate which is defined as the rate per annum equal to the greatest of (a) the lender’s prime rate, (b) the weighted average of the federal funds rate, plus 0.5% and (c) one month LIBOR rate plus 1%, in each case, plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 0.375% to 0.625% for revolving credit and term loan A borrowings and 0.75% for tranche B borrowings, or (2) the one, two, three or six month LIBOR rate (at our election), plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 1.375% to 1.625% for revolving credit and term loan A borrowings and 1.75% for the tranche B term loan. As of June 30, 2020, the applicable margins were 0.375% for ABR-based loans and 1.375% for LIBOR-based loans under the revolving credit and term loan A facilities. The revolving credit facility includes a $125 million sub-limit for letters of credit. The Senior Credit Agreement is secured by certain assets of the Company and our material subsidiaries (which generally excludes asset classes such as substantially all of the patient-related accounts receivable of our acute care hospitals, and certain real estate assets and assets held in joint-ventures with third parties) and is guaranteed by our material subsidiaries. The Senior Credit Agreement includes a material adverse change clause that must be represented at each draw. The Senior Credit Agreement contains covenants that include a limitation on sales of assets, mergers, change of ownership, liens and indebtedness, transactions with affiliates, dividends and stock repurchases; and requires compliance with financial covenants including maximum leverage. We are in compliance with all required covenants as of June 30, 2020 and December 31, 2019. In late April, 2018, we entered into the sixth amendment to our accounts receivable securitization program (“Securitization”) dated as of October 27, 2010 with a group of conduit lenders, liquidity banks, and PNC Bank, National Association, as administrative agent, which provides for borrowings outstanding from time to time by certain of our subsidiaries in exchange for undivided security interests in their respective accounts receivable. The sixth amendment, among other things, extended the term of the Securitization program through April 26, 2021 and increased the borrowing capacity to $450 million (from $440 million previously). In July, 2020, we entered into the seventh amendment to the Securitization which temporarily waives a minimum borrowing requirement. Pursuant to the terms of our Securitization program, substantially all of the patient-related accounts receivable of our acute care hospitals (“Receivables”) serve as collateral for the outstanding borrowings. We have accounted for this Securitization as borrowings. We maintain effective control over the Receivables since, pursuant to the terms of the Securitization, the Receivables are sold from certain of our subsidiaries to special purpose entities that are wholly-owned by us. The Receivables, however, are owned by the special purpose entities, can be used only to satisfy the debts of the wholly-owned special purpose entities, and thus are not available to us except through our ownership interest in the special purpose entities. The wholly-owned special purpose entities use the Receivables to collateralize the loans obtained from the group of third-party conduit lenders and liquidity banks. The group of third-party conduit lenders and liquidity banks do not have recourse to us beyond the assets of the wholly-owned special purpose entities that securitize the loans. At June 30, 2020, we had no Securitization borrowings outstanding and, pursuant to the terms and conditions of the program, we had approximately $378 million of available borrowing capacity. As of June 30, 2020, we had combined aggregate principal of $1.1 billion from the following senior secured notes: • $700 million aggregate principal amount of 4.75% senior secured notes due in August, 2022 (“2022 Notes”) which were issued as follows: • $300 million aggregate principal amount issued on August 7, 2014 at par. • $400 million aggregate principal amount issued on June 3, 2016 at 101.5% to yield 4.35%. • $400 million aggregate principal amount of 5.00% senior secured notes due in June, 2026 (“2026 Notes”) which were issued on June 3, 2016. Interest on the 2022 Notes is payable on February 1 and August 1 of each year until the maturity date of August 1, 2022. Interest on the 2026 Notes is payable on June 1 and December 1 until the maturity date of June 1, 2026. The 2022 Notes and 2026 Notes were offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The 2022 Notes and 2026 Notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. On November 26, 2018 we redeemed the $300 million aggregate principal, 3.75% Senior Notes due in 2019. The 2019 Notes were redeemed for an aggregate price equal to 100.485% of the principal amount, resulting in a premium paid of approximately $1 million, plus accrued interest to the redemption date. At June 30, 2020, the carrying value and fair value of our debt were each approximately $3.5 billion approximately $4.0 billion. Cash Flow Hedges: We manage our ratio of fixed and floating rate debt with the objective of achieving a mix that management believes is appropriate. To manage this risk in a cost-effective manner, we, from time to time, enter into interest rate swap agreements in which we agree to exchange various combinations of fixed and/or variable interest rates based on agreed upon notional amounts. We account for our derivative and hedging activities using the Financial Accounting Standard Board’s guidance which requires all derivative instruments, including certain derivative instruments embedded in other contracts, to be carried at fair value on the balance sheet. For derivative transactions designated as hedges, we formally document all relationships between the hedging instrument and the related hedged item, as well as its risk-management objective and strategy for undertaking each hedge transaction. Derivative instruments designated in a hedge relationship to mitigate exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or liability, with a corresponding amount recorded in accumulated other comprehensive income (“AOCI”) within shareholders’ equity. Amounts are reclassified from AOCI to the income statement in the period or periods the hedged transaction affects earnings. From time to time, we use interest rate derivatives in our cash flow hedge transactions. Such derivatives are designed to be highly effective in offsetting changes in the cash flows related to the hedged liability. For hedge transactions that do not qualify for the short-cut method, at the hedge’s inception and on a regular basis thereafter, a formal assessment is performed to determine whether changes in the fair values or cash flows of the derivative instruments have been highly effective in offsetting changes in cash flows of the hedged items and whether they are expected to be highly effective in the future. The fair value of interest rate swap agreements approximates the amount at which they could be settled, based on estimates obtained from the counterparties. When applicable, we assess the effectiveness of our hedge instruments on a quarterly basis. Although we do not anticipate nonperformance by our counterparties to interest rate swap agreements, the counterparties expose us to credit risk in the event of nonperformance. We do not hold or issue derivative financial instruments for trading purposes. During 2015, we entered into nine forward starting interest rate swaps whereby we paid a fixed rate on a total notional amount of $1.0 billion and received one-month LIBOR. The average fixed rate payable on these swaps, all of which matured on April 15, 2019, was 1.31%. When applicable, we measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from our counterparties. We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. Foreign Currency Forward Exchange Contracts: In August 2017, the FASB issued new guidance on hedge accounting (ASU 2017-12) that is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new guidance amends the presentation and disclosure requirements, and changes how companies assess effectiveness. We adopted this guidance as of January 1, 2019 and applied to all existing hedges as of the adoption date. We use forward exchange contracts to hedge our net investment in foreign operations against movements in exchange rates. The effective portion of the unrealized gains or losses on these contracts is recorded in foreign currency translation adjustment within accumulated other comprehensive income and remains there until either the sale or liquidation of the subsidiary. In connection with these forward exchange contracts, we recorded net cash inflows of $57 million and $5 million during the six-month periods ended June 30, 2020 and 2019, respectively. During the fourth quarter of 2019, we identified certain cash inflows related to operating activities that were incorrectly classified as cash inflows from foreign currency exchange contracts, as included cash flows from investing activities, on our condensed consolidated statements of cash flows for the quarterly periods in 2019. The cash flows related to our foreign currency exchange contracts were correctly classified on our consolidated statements of cash flows for the year ended December 31, 2019. We determined that these misclassifications were not material to the financial statements of any period during 2019. However, in order to improve the consistency and comparability of the financial statements, we have revised the condensed consolidated statements of cash flows for the six-month period ended June 3 0 , 2019. Derivatives Hedging Relationships: The following table presents the effects of our interest rate swap agreements and our foreign currency foreign exchange contracts on our results of operations for the three and six-month periods ended June 30, 2020 and 2019 (in thousands): Gain/(Loss) recognized in AOCI Three months ended Six months ended June 30, June 30, June 30, June 30, 2020 2019 2020 2019 Cash Flow Hedge relationships Interest rate swap agreements (a) $ 0 $ (1,008 ) $ 0 $ (3,925 ) Net Investment Hedge relationships Foreign currency foreign exchange contracts $ 2,989 $ 40,436 $ 43,535 $ 45,657 (a) The amount of gain reclassified out of AOCI into interest expense, net was $0 and $456,000 during the three-month periods ended June 30, 2020 and 2019, respectively, and $0 and $3.4 million during the six-month periods ended June 30, 2020 and 2019, respectively. No other gains or losses were recognized in income related to derivatives in Subtopic 815-20. Cash, Cash Equivalents and Restricted Cash: Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follow (in thousands): June 30, December 31, 2020 2019 Cash and cash equivalents $ 539,622 $ 61,268 Restricted cash and cash equivalents (a) 44,650 44,399 Total cash, cash equivalents and restricted cash $ 584,272 (b) $ 105,667 (a) Restricted cash and cash equivalents is included in other assets on the accompanying consolidated balance sheet. (b) Consists primarily of short-term cash accounts on which interest is being earned at various annual rates ranging from 0.10% to 0.65%.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	(5) Fair Value Measurement Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These included quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) June 30, 2020 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds $ 174,200 Cash and cash equivalents 174,200 Term Deposit 100,000 Cash and cash equivalents 100,000 Money market mutual funds 60,870 Other assets 60,870 Certificates of deposit 2,201 Other assets 2,201 Available for sale securities 63,780 Other assets 63,780 Deferred compensation assets 31,292 Other assets 31,292 Foreign currency exchange contracts 2,187 Other current assets 2,187 $ 434,530 332,343 102,187 - Liabilities: Deferred compensation liability 31,292 Other noncurrent liabilities 31,292 $ 31,292 31,292 - - Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) December 31, 2019 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds $ 60,175 Other assets 60,175 Certificates of deposit 2,200 Other assets 2,200 Available for sale securities 70,478 Other assets 70,478 Deferred compensation assets 35,510 Other assets 35,510 Foreign currency exchange contracts 10,343 Other current assets 10,343 $ 178,706 168,363 10,343 - Liabilities: Deferred compensation liability $ 35,510 Other noncurrent liabilities 35,510 $ 35,510 35,510 - - The fair value of our money market mutual funds, certificates of deposit and available for sale securities are computed based upon quoted market prices in active market. The fair value of deferred compensation assets and offsetting liability are computed based on market prices in an active market held in a rabbi trust. The fair value of our interest rate swaps are based on quotes from our counter parties. The fair value of our foreign currency exchange contracts is valued using quoted forward exchange rates and spot rates at the reporting date.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(6) Commitments and Contingencies Professional and General Liability, Workers’ Compensation Liability The vast majority of our subsidiaries are self-insured for professional and general liability exposure up to: (i) $10 million and $3 million per occurrence, respectively, effective January, 2020 (professional liability claims are also subject to an additional annual aggregate self-insured retention of $2.5 million for claims in excess of $10 million); (ii) $5 million and $3 million per occurrence, respectively, during 2019, 2018 and 2017, and; (iii) $10 million and $3 million per occurrence, respectively, prior to 2017. These subsidiaries are provided with several excess policies through commercial insurance carriers which provide for coverage in excess of the applicable per occurrence self-insured retention or underlying policy limits incurred after 2013 a As of June 30, 2020, the total accrual for our professional and general liability claims was $250 million, of which $42 million was included in current liabilities. As of December 31, 2019, the total accrual for our professional and general liability claims was $242 million, of which $42 million was included in current liabilities. As a result of unfavorable trends recently experienced, during the first six months of 2020, we have recorded a $20 million increase to our reserves for self-insured professional and general liability claims, which was recorded during the first quarter. Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. While we continuously monitor these factors, our ultimate liability for professional and general liability claims could change materially from our current estimates due to inherent uncertainties involved in making this estimate. Given our significant self-insured exposure for professional and general liability claims, there can be no assurance that a sharp increase in the number and/or severity of claims asserted against us will not have a material adverse effect on our future results of operations. Although we are unable to predict whether or not our future financial statements will require updates to estimates for our prior year reserves for self-insured general and professional and workers’ compensation claims, given the relatively unpredictable nature of the these potential liabilities and the factors impacting these reserves, as discussed above, it is reasonably likely that our future financial results may include material adjustments to prior period reserves. As of June 30, 2020, the total accrual for our workers’ compensation liability claims was $90 million, of which $40 million was included in current liabilities. As of December 31, 2019, the total accrual for our workers’ compensation liability claims was $81 million, of which $40 million was included in current liabilities. Property Insurance We have commercial property insurance policies for our properties covering catastrophic losses, including windstorm damage, up to a $1 billion policy limit, subject to a per occurrence/per location deductible of $2.5 million as of June 1, 2020. Losses resulting from named windstorms are subject to deductibles between 3% and 5% of the total insurable value of the property. In addition, we have commercial property insurance policies covering catastrophic losses resulting from earthquake and flood damage, each subject to aggregated loss limits (as opposed to per occurrence losses). Commercially insured earthquake coverage for our facilities is subject to various deductibles and limitations including: (i) $500 million limitation for our facilities located in Nevada; (ii) $130 million limitation for our facilities located in California; (iii) $100 million limitation for our facilities located in fault zones within the United States; (iv) $40 million limitation for our facilities located in Puerto Rico, and; (v) $250 million limitation for many of our facilities located in other states. Our commercially insured flood coverage has a limit of $100 million annually. There is also a $10 million sublimit for one of our facilities located in Houston, Texas, and a $1 million sublimit for our facilities located in Puerto Rico. Property insurance for our behavioral health facilities located in the U.K. are provided on an all risk basis up to a £1.5 billion policy limit, with coverage caps per location, that includes coverage for real and personal property as well as business interruption losses. Legal Proceedings We operate in a highly regulated and litigious industry which subjects us to various claims and lawsuits in the ordinary course of business as well as regulatory proceedings and government investigations. These claims or suits include claims for damages for personal injuries, medical malpractice, commercial/contractual disputes, wrongful restriction of, or interference with, physicians’ staff privileges, and employment related claims. In addition, health care companies are subject to investigations and/or actions by various state and federal governmental agencies or those bringing claims on their behalf. Government action has increased with respect to investigations and/or allegations against healthcare providers concerning possible violations of fraud and abuse and false claims statutes as well as compliance with clinical and operational regulations. Currently, and from time to time, we and some of our facilities are subjected to inquiries in the form of subpoenas, Civil Investigative Demands, audits and other document requests from various federal and state agencies. These inquiries can lead to notices and/or actions including repayment obligations from state and federal government agencies associated with potential non-compliance with laws and regulations. Further, the federal False Claims Act allows private individuals to bring lawsuits (qui tam actions) against healthcare providers that submit claims for payments to the government. Various states have also adopted similar statutes. When such a claim is filed, the government will investigate the matter and decide if they are going to intervene in the pending case. These qui tam lawsuits are placed under seal by the court to comply with the False Claims Act’s requirements. If the government chooses not to intervene, the private individual(s) can proceed independently on behalf of the government. Health care providers that are found to violate the False Claims Act may be subject to substantial monetary fines/penalties as well as face potential exclusion from participating in government health care programs or be required to comply with Corporate Integrity Agreements as a condition of a settlement of a False Claims Act matter. In September 2014, the Criminal Division of the Department of Justice (“DOJ”) announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The DOJ has also announced an intention to pursue civil and criminal actions against individuals within a company as well as the corporate entity or entities. In addition, health care facilities are subject to monitoring by state and federal surveyors to ensure compliance with program Conditions of Participation. In the event a facility is found to be out of compliance with a Condition of Participation and unable to remedy the alleged deficiency(s), the facility faces termination from the Medicare and Medicaid programs or compliance with a System Improvement Agreement to remedy deficiencies and ensure compliance. The laws and regulations governing the healthcare industry are complex covering, among other things, government healthcare participation requirements, licensure, certification and accreditation, privacy of patient information, reimbursement for patient services as well as fraud and abuse compliance. These laws and regulations are constantly evolving and expanding. Further, the Legislation has added additional obligations on healthcare providers to report and refund overpayments by government healthcare programs and authorizes the suspension of Medicare and Medicaid payments “pending an investigation of a credible allegation of fraud.” We monitor our business and have developed an ethics and compliance program with respect to these complex laws, rules and regulations. Although we believe our policies, procedures and practices comply with government regulations, there is no assurance that we will not be faced with the sanctions referenced above which include fines, penalties and/or substantial damages, repayment obligations, payment suspensions, licensure revocation, and expulsion from government healthcare programs. Even if we were to ultimately prevail in any action brought against us or our facilities or in responding to any inquiry, such action or inquiry could have a material adverse effect on us. Certain legal matters are described below: Government Investigations - UHS Behavioral Health As previously announced in July, 2019, Universal Health Services, Inc. (“we”, the “Company”) had reached an agreement in principle with the Department of Justice’s Civil Division, and various states’ attorneys general offices, to resolve the civil aspects of the government’s investigation of our behavioral health care facilities for $127 million subject to requisite approvals and preparation and execution of definitive settlement and related agreements. On July 6, 2020, and as previously disclosed on Form 8-K as filed on July 10, 2020, pursuant to terms and amounts consistent with the previously announced agreement in principle, definitive settlement agreements (“Settlement Agreements”) were fully executed thereby resolving this matter. The Company denies the allegations raised in this matter and the settlement does not constitute an admission of facts or liability by the Company or any of its subsidiary behavioral health facilities. Pursuant to the terms of the settlement agreements, on July 9, 2020, we made net aggregate payments of approximately $117.3 million, before accrued interest and related fees, costs and individual claims due to or on behalf of third-parties, consisting of the following: • $88.1 million pursuant to the terms of the agreement with the Department of Justice (“DOJ”) and Office of Inspector General for the United States Department of Health and Human Services (“OIG”); • $28.9 million to various individual states that participated in the settlement; • $10.0 million in connection with the settlement of the U.S. ex rel Escobar v. Universal Health Services, Inc. et.al . and U.S. et. al. ex rel Correa et. al. v. Universal Health Services, Inc. et. al. matters, False Claims Act cases filed against Universal Health Services, Inc., UHS of Delaware, Inc. and HRI Clinics, Inc. d/b/a Arbour Counseling Services in U.S. District Court for the District of Massachusetts; • less approximately $9.7 million of aggregate funds previously withheld from us in connection with the previously disclosed River Point Behavioral Health payment suspension and a suspension of payments to the Lawrence campus of Arbour Counseling Services associated with the Escobar matter. These previously withheld amounts are credited against the amounts due from us under the Settlement Agreements. As a condition of the settlement, the payment suspension at River Point will be lifted. The Lawrence campus of Arbour Counseling was previously closed by us. In addition, we have also reached agreement in principle resolving all claims for attorneys’ fees and costs of the relators, as well as any individual claims of the relators, amounting to approximately $6.0 million in the aggregate, pending finalization and execution of the remaining settlement agreements with the relators. We also paid accrued interest on the settlement amounts for certain specified periods of approximately two months or less at annual rates of either 2.125% or 1.250% which amounted to approximately $230,000 in the aggregate. We had previously established a pre-tax reserve in connection with the settlements and matters discussed above, which includes related fees and costs due to or on behalf of third-parties, which amounted to approximately $134 million at both March 31, 2020 and December 31, 2019. The final aggregate settlement amounts, together with accrued interest and related fees and costs, did not differ materially from the previously established reserves. Under the settlement agreements, the United States and the participating states agree to release the Company and its behavioral health subsidiaries from any civil or administrative monetary liability arising from the Covered Conduct as specified in the Agreements. Additionally, under the settlement agreement, the United States, participating states and the relators agreed to dismiss the civil actions filed by the relators under the qui tam foregoing description of the Settlement Agreements are qualified in its entirety by reference to the full text of those agreements, which were attached as Exhibit 10.1 and 10.2 to our Form 8-K as filed on July 10, 2020 and incorporated herein by reference. In connection with the resolution of this matter, and in exchange for the OIG’s agreement not to exclude the Company and its behavioral health subsidiaries from participating in the federal health care programs, the Company entered into a five-year foregoing description of the Corporate Integrity Agreement is qualified in its entirety by reference to the full text of that agreement, which was attached as Exhibit 10.3 to our Form 8-K as filed on July 10, 2020 and incorporated herein by reference. DOJ investigation of Turning Point Hospital . During the fourth quarter of 2018, we were notified that the DOJ Civil Division in conjunction with the U.S. Attorney’s Office for the Northern District of Georgia and the Georgia Attorney General’s Office opened an investigation of Turning Point Hospital in Moultrie, GA. The DOJ Civil Division advised us that they were primarily investigating transportation and housing financial assistance provided to patients receiving treatment at the facility. The DOJ issued a civil investigative demand to the facility requesting various documents and other information. In September, 2019, we reached a settlement in principle of this matter pending negotiation, finalization and execution of definitive settlement agreements. The settlement agreement was finalized and executed in July, 2020. As of June 30, 2020 and December 31, 2019, our financial statements included an estimated reserve in connection with the potential settlement of this matter, which did not have material impact on our results of operations and financial condition. Litigation: Shareholder Class Action In December 2016 a purported shareholder class action lawsuit was filed in U.S. District Court for the Central District of California against UHS and certain UHS officers alleging violations of the federal securities laws. The case was originally filed as Heed v. Universal Health Services, Inc. et. al. (Case No. 2:16-CV-09499-PSG-JC). The court subsequently appointed Teamsters Local 456 Pension Fund and Teamsters Local 456 Annuity Fund to serve as lead plaintiffs. The case has been transferred to the U.S. District Court for the Eastern District of Pennsylvania and the style of the case has been changed to Teamsters Local 456 Pension Fund, et. al. v. Universal Health Services, Inc. et. al. (Case No. 2:17-CV-02817-LS). In September, 2017, Teamsters Local 456 Pension Fund filed an amended complaint. The amended class action complaint alleges violations of federal securities laws relating to disclosures made in public filings associated with alleged practices and operations at our behavioral health facilities. Plaintiffs seek monetary damages for shareholders during the defined class period as a result of the decrease in share price following various public disclosures or reports. In December, 2017, we filed a motion to dismiss the amended complaint. In August, 2019, the court granted our motion to dismiss. Plaintiffs subsequently filed a motion with the court seeking leave to file a second amended complaint. In April, 2020, the court denied Plaintiffs’ motion to file a second amended complaint. Plaintiffs have filed an appeal with the 3d Circuit Court of Appeals. We deny liability and intend to defend ourselves vigorously. At this time, we are uncertain as to potential liability or financial exposure, if any, which may be associated with this matter. Shareholder Derivative Cases In March 2017, a shareholder derivative suit was filed by plaintiff David Heed in the Court of Common Pleas of Philadelphia County. A notice of removal to the United States District Court for the Eastern District of Pennsylvania was filed (Case No. 2:17-cv-01476- LS). Plaintiff filed a motion to remand. In December 2017, the Court denied plaintiff’s motion to remand and retained the case in federal court. In May, June and July 2017, additional shareholder derivative suits were filed in the United States District Court for the Eastern District of Pennsylvania. The plaintiffs in those cases are: Central Laborers’ Pension Fund (Case No. 17-cv-02187-LS); Firemen’s Retirement System of St. Louis (Case No. 17—cv-02317-LS); Waterford Township Police & Fire Retirement System (Case No. 17-cv-02595-LS); and Amalgamated Bank Longview Funds (Case No. 17-cv-03404-LS). The Fireman’s Retirement System case has since been voluntarily dismissed. The federal court c onsolidated all of the cases pending in the Eastern District of Pennsylvania and appointed co-lead plaintiffs and co-lead counsel. Lead Plaintiffs filed a consolidated, amended complaint. We filed a motion to dismiss the amended complaint. In addition, a shareholder derivative case was filed in Chancery Court in Delaware by the Delaware County Employees’ Retirement Fund (Case No. 2017-0475-JTL). In December 2017, the Chancery Court stayed this case pending resolution of other contemporaneous matters. Each of these cases have named certain current and former members of the Board of Directors individually and certain officers of Universal Health Services, Inc. as defendants. UHS has also been named as a nominal defendant in these cases. The derivative cases make substantially similar allegations and claims as the shareholder class action relating to practices at our behavioral health facilities and board and corporate oversight of these facilities as well as claims relating to the stock trading by the individual defendants and company repurchase of shares during the relevant time period. The cases make claims of breaches of fiduciary duties by the named board members and officers; alleged violations of federal securities laws; and common law causes of action against the individual defendants including unjust enrichment, corporate waste, abuse of control, constructive fraud and gross mismanagement. The cases seek monetary damages allegedly incurred by the company; restitution and disgorgement of profits, benefits and other compensation from the individual defendants and various forms of equitable relief relating to corporate governance matters. In August, 2019, the court granted our motion to dismiss. Plaintiffs subsequently filed a motion with the court seeking leave to file a second amended complaint. In April, 2020, the court denied Plaintiffs motion to file a second amended complaint. Plaintiffs have filed an appeal with the 3d Circuit Court of Appeals. The defendants deny liability and intend to defend these cases vigorously. At this time, we are uncertain as to potential liability or financial exposure, if any, which may be associated with these matters. The George Washington University v. Universal Health Services, Inc., et. al. In December 2019, The George Washington University (“University”) filed a lawsuit in the Superior Court for the District of Columbia against Universal Health Services, Inc. as well as certain subsidiaries and individuals associated with the ownership and management of The George Washington University Hospital (“GW Hospital”) in Washington, D.C. (case No. 2019 CA 008019 B). The lawsuit claims that UHS failed to provide sufficient financial compensation to the University under the terms of various agreements entered into in 1997 between the University and UHS for the joint venture ownership of GW Hospital. The lawsuit includes claims for breach of contract, breach of fiduciary duty, and unjust enrichment. We deny liability and intend to defend this matter vigorously. We filed a motion to dismiss the complaint. In June, 2020, the Court granted the motion in part dismissing the majority of the claims against UHS. At this time, we are uncertain as to potential liability or financial exposure, if any, which may be associated with this matter. Disproportionate Share Hospital Payment Matter: In late September, 2015, many hospitals in Pennsylvania, including certain of our behavioral health care hospitals located in the state, received letters from the Pennsylvania Department of Human Services (the “Department”) demanding repayment of allegedly excess Medicaid Disproportionate Share Hospital payments (“DSH”), primarily consisting of managed care payments characterized as DSH payments, for the federal fiscal year (“FFY”) 2011 amounting to approximately $4 million in the aggregate. Since that time, certain of our behavioral health care hospitals in Pennsylvania have received similar requests for repayment for alleged DSH overpayments for FFYs 2012 through 2015. For FFY 2012, the claimed overpayment amounts to approximately $4 million. For FY 2013, FY 2014 and FY 2015 the initial claimed overpayments and attempted recoupment by the Department were approximately $7 million, $8 million and $7 million, respectively. The Department has agreed to a change in methodology which, upon confirmation of the underlying data being accepted by the Department, could reduce the initial claimed overpayments for FY 2013, FY 2014 and FY 2015 to approximately $2 million, $2 million and $3 million, respectively. We filed administrative appeals for all of our facilities contesting the recoupment efforts for FFYs 2011 through 2015 as we believe the Department’s calculation methodology is inaccurate and conflicts with applicable federal and state laws and regulations. The Department has agreed to postpone the recoupment of the state’s share for FY 2011 to 2013 until all hospital appeals are resolved but started recoupment of the federal share. For FY 2014 and FY 2015, the Department has initiated the recoupment of the alleged overpayments. Starting in FFY 2016, the first full fiscal year after the January 1, 2015 effective date of Medicaid expansion in Pennsylvania, the Department no longer characterized managed care payments received by the hospitals as DSH payments. We can provide no assurance that we will ultimately be successful in our legal and administrative appeals related to the Department’s repayment demands. If our legal and administrative appeals are unsuccessful, our future consolidated results of operations and financial condition could be adversely impacted by these repayments. Other Matters: Various other suits, claims and investigations, including government subpoenas, arising against, or issued to, us are pending and additional such matters may arise in the future. Management will consider additional disclosure from time to time to the extent it believes such matters may be or become material. The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters described above or that are otherwise pending because the inherently unpredictable nature of legal proceedings may be exacerbated by various factors, including, but not limited to: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the matter is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties, or; (vii) there is a wide range of potential outcomes. It is possible that the outcome of these matters could have a material adverse impact on our future results of operations, financial position, cash flows and, potentially, our reputation.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	(7) Segment Reporting Our reportable operating segments consist of acute care hospital services and behavioral health care services. The “Other” segment column below includes centralized services including, but not limited to, information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising and design and construction. The chief operating decision making group for our acute care services and behavioral health care services is comprised of our Chief Executive Officer, the President and the Presidents of each operating segment. The Presidents for each operating segment also manage the profitability of each respective segment’s various facilities. The operating segments are managed separately because each operating segment represents a business unit that offers different types of healthcare services or operates in different healthcare environments. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2019. The corporate overhead allocations, as reflected below, are utilized for internal reporting purposes and are comprised of each period’s projected corporate-level operating expenses (excluding interest expense). The overhead expenses are captured and allocated directly to each segment to the extent possible, and overhead expenses incurred on behalf of both segments are captured and allocated to each segment based upon each segment’s respective percentage of total operating expenses. Three months ended June 30, 2020 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 6,736,777 $ 2,285,359 $ - $ 9,022,136 Gross outpatient revenues $ 3,394,680 $ 216,174 $ - $ 3,610,854 Total net revenues $ 1,467,506 $ 1,259,123 $ 3,125 $ 2,729,754 Income/(loss) before allocation of corporate overhead and income taxes $ 182,996 $ 256,766 $ (104,104 ) $ 335,658 Allocation of corporate overhead $ (55,983 ) $ (42,750 ) $ 98,733 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 127,013 $ 214,016 $ (5,371 ) $ 335,658 Total assets as of June 30, 2020 $ 4,467,698 $ 6,819,694 $ 861,107 $ 12,148,499 Six months ended June 30, 2020 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 14,558,249 $ 4,810,898 $ 0 $ 19,369,147 Gross outpatient revenues $ 8,076,421 $ 475,913 $ 0 $ 8,552,334 Total net revenues $ 2,988,555 $ 2,565,232 $ 5,634 $ 5,559,421 Income/(loss) before allocation of corporate overhead and income taxes $ 286,533 $ 494,449 $ (254,541 ) $ 526,441 Allocation of corporate overhead $ (111,956 ) $ (85,480 ) $ 197,436 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 174,577 $ 408,969 $ (57,105 ) $ 526,441 Total assets as of June 30, 2020 $ 4,467,698 $ 6,819,694 $ 861,107 $ 12,148,499 Three months ended June 30, 2019 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 7,051,925 $ 2,547,626 $ 0 $ 9,599,551 Gross outpatient revenues $ 4,402,308 $ 268,693 $ 0 $ 4,671,001 Total net revenues $ 1,531,709 $ 1,320,241 $ 3,218 $ 2,855,168 Income/(loss) before allocation of corporate overhead and income taxes $ 188,157 $ 265,986 $ (143,335 ) $ 310,808 Allocation of corporate overhead $ (57,528 ) $ (41,638 ) $ 99,166 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 130,629 $ 224,348 $ (44,169 ) $ 310,808 Total assets as of June 30, 2019 $ 4,413,509 $ 6,933,825 $ 405,316 $ 11,752,650 Six months ended June 30, 2019 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 14,215,639 $ 5,031,625 $ 0 $ 19,247,264 Gross outpatient revenues $ 8,659,922 $ 535,239 $ 0 $ 9,195,161 Total net revenues $ 3,046,553 $ 2,606,624 $ 6,382 $ 5,659,559 Income/(loss) before allocation of corporate overhead and income taxes $ 380,370 $ 510,154 $ (283,420 ) $ 607,104 Allocation of corporate overhead $ (115,028 ) $ (83,285 ) $ 198,313 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 265,342 $ 426,869 $ (85,107 ) $ 607,104 Total assets as of June 30, 2019 $ 4,413,509 $ 6,933,825 $ 405,316 $ 11,752,650 (a) Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $136 million and $144 million for the three-month periods ended June 30, 2020 and 2019, respectively, and approximately $273 million and $281 million for the six-month periods ended June 30, 2020 and 2019, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.192 billion and $1.217 billion as of June 30, 2020 and 2019, respectively.

Earnings Per Share Data ("EPS")

Earnings Per Share Data ("EPS") and Stock Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Earnings Per Share Data ("EPS") and Stock Based Compensation	(8) Earnings Per Share Data (“EPS”) and Stock Based Compensation Basic earnings per share are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share are based on the weighted average number of common shares outstanding during the period adjusted to give effect to common stock equivalents. The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Three months ended June 30, Six months ended June 30, 2020 2019 2020 2019 Basic and Diluted: Net income attributable to UHS $ 251,929 $ 238,320 $ 393,966 $ 472,488 Less: Net income attributable to unvested restricted share grants (824 ) (656 ) (1,197 ) (1,171 ) Net income attributable to UHS – basic and diluted $ 251,105 $ 237,664 $ 392,769 $ 471,317 Weighted average number of common shares - basic 84,632 89,136 85,422 89,956 Net effect of dilutive stock options and grants based on the treasury stock method 427 99 335 145 Weighted average number of common shares and equivalents - diluted 85,059 89,235 85,757 90,101 Earnings per basic share attributable to UHS: $ 2.97 $ 2.67 $ 4.60 $ 5.24 Earnings per diluted share attributable to UHS: $ 2.95 $ 2.66 $ 4.58 $ 5.23 The “Net effect of dilutive stock options and grants based on the treasury stock method”, for all periods presented above, excludes certain outstanding stock options applicable to each period since the effect would have been anti-dilutive. The excluded weighted-average stock options totaled 7.1 million for the three months ended June 30, 2020 and 6.5 million for the six months ended June 30, 2020. The excluded weighted-average stock options totaled 8.5 million for the three months ended June 30, 2019 and 7.8 million for the six months ended June 30, 2019. All classes of our common stock have the same dividend rights. The decrease in our basic and diluted weighted number of common shares outstanding for the three and six months ended June 30, 2020, as compared to the comparable prior year three and six months, was due primarily to the impact of shares repurchased by us since January 1, 2019. Stock-Based Compensation: During the three-month periods ended June 30, 2020 and 2019, pre-tax compensation cost of $13.2 million and $14.7 million, respectively, was recognized related to outstanding stock options. During the six-month periods ended June 30, 2020 and 2019, pre-tax compensation costs of $28.6 million and $30.5 million, respectively, was recognized related to outstanding stock options. In addition, during the three-month periods ended June 30, 2020 and 2019, pre-tax compensation cost of approximately $2.4 million and $2.1 million (net of cancellations), respectively, was recognized related to restricted stock. During the six-months periods ended June 30, 2020 and 2019, pre-tax compensation costs of approximately $4.7 million and $3.7 million (net of cancellations), respectively, was recognized related to restricted stock. As of June 30, 2020 there was approximately $128.1 million of unrecognized compensation cost related to unvested options and restricted stock which is expected to be recognized over the remaining weighted average vesting period of 2.6 years The expense associated with stock-based compensation arrangements is a non-cash charge. In the Condensed Consolidated Statements of Cash Flows, stock-based compensation expense is an adjustment to reconcile net income to cash provided by operating activities and aggregated to $34.0 million and $34.7 million during the six month periods ended June 30, 2020 and 2019, respectively.

Dispositions and acquisitions

Dispositions and acquisitions	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Dispositions and acquisitions	(9) Dispositions and acquisitions Six-month period ended June 30, 2020: Acquisitions: During the first six months of 2020, we spent $1 million on the acquisition of businesses and property. Divestitures: During the first six months of 2020, we received $6 million from the sale of assets and businesses. Six-month period ended June 30, 2019: Acquisitions: During the first six months of 2019, there were no acquisitions. Divestitures: During the first six months of 2019, there were no divestitures.

Dividends

Dividends	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Dividends	(10) Dividends We declared and paid dividends of $17.3 million, or $.20 per share, during the first quarter of 2020. As part of our various COVID-19 initiatives, we have suspended declaration and payments of quarterly dividends. We declared and paid dividends of $8.9 million, or $.10 per share, during the second quarter of 2019 and declared and paid dividends of $18.0 million during the six-month period ended June 30, 2019 .

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	(11) Income Taxes Our effective income tax rates were 23.6% and 22.4% during the three-month periods ended June 30, 2020, and 2019, respectively, and 23.8% and 21.2% during the six-month periods ended June 30, 2020, and 2019, respectively. The increase in the effective tax rate during the three-month period ended June 30, 2020, as compared to the comparable quarter of 2019, was primarily due to a $4 million increase resulting from a favorable adjustment to the income tax provision related to the effects of a change in state tax law enacted during the second quarter of 2019. The increase in the effective tax rate during the six-month period ended June 30, 2020, compared with the same period in 2019, was primarily due to a $12 million unfavorable change in the tax benefit from employee share-based payments and a $4 million increase resulting from a favorable adjustment to the income tax provision related to the effects of a change in state tax law enacted during the second quarter of 2019, which increased our provision for income taxes by $1 million during the first six months of 2020 as compared to a $15 million tax benefit during the first six months of 2019. The global intangible low-taxed income (“GILTI”) provisions from the TCJA-17 require the inclusion of the earnings of certain foreign subsidiaries in excess of an acceptable rate of return on certain assets of the respective subsidiaries in our U.S. tax return for tax years beginning after December 31, 2017. An accounting policy election was made during 2018 to treat taxes related to GILTI as a period cost when the tax is incurred. We recorded a GILTI tax provision of zero and less than $1 million for the six months ended June 30, 2020 and 2019, respectfully. As of January 1, 2020, our unrecognized tax benefits were approximately $2 million. The amount, if recognized, that would favorably affect the effective tax rate is approximately $2 million. During the six months ended June 30, 2020, changes to the estimated liabilities for uncertain tax positions (including accrued interest) relating to tax positions taken during prior and current periods did not have a material impact on our financial statements. We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. As of June 30, 2020, we have less than $1 million of accrued interest and penalties. The U.S. federal statute of limitations remains open for 2016 and subsequent years. Foreign and U.S. state and local jurisdictions have statutes of limitations generally ranging from 3 to 4 years. The statute of limitations on certain jurisdictions could expire within the next twelve months. It is reasonably possible that the amount of uncertain tax benefits will change during the next 12 months, however, it is anticipated that any such change, if it were to occur, would not have a material impact on our results of operations. We operate in multiple jurisdictions with varying tax laws. We are subject to audits by any of these taxing authorities. Our tax returns have been examined by the Internal Revenue Service (“IRS”) through the year ended December 31, 2006. We believe that adequate accruals have been provided for federal, foreign and state taxes.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue	(12) Revenue The company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Or estimate for amounts not expected to be collected based on historical experience will continue to be recognized as a reduction to net revenue. However, subsequent changes in estimate of collectability due to a change in the financial status of a payer, for example a bankruptcy, will be recognized as bad debt expense in operating charges. The performance obligation is separately identifiable from other promises in the customer contract. As the performance obligations are met (i.e.: room, board, ancillary services, level of care), revenue is recognized based upon allocated transaction price. price is allocated to separate performance obligations based upon the relative standalone selling price. In instances where we determine there are multiple performance obligations across multiple months, the transaction price will be allocated by applying an estimated implicit and explicit rate to gross charges based on the separate performance obligations . In assessing collectability, we have elected the portfolio approach. This portfolio approach is being used as we have large volume of similar contracts with similar classes of customers. We reasonably expect that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Management’s judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers, will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level. We group our revenues into categories based on payment behaviors. Each component has its own reimbursement structure which allows us to disaggregate the revenue into categories that share the nature and timing of payments. The other patient revenue consists primarily of self-pay, government-funded non-Medicaid, and other. The following table disaggregates our revenue by major source for the three and six month periods ended June 30, 2020 and 2019 (in thousands): For the three months ended June 30, 2020 Acute Care Behavioral Health Other Total Medicare $ 264,310 18 % $ 106,571 8 % $ 370,881 14 % Managed Medicare 182,771 12 % 59,979 5 % 242,750 9 % Medicaid 131,452 9 % 154,090 12 % 285,542 10 % Managed Medicaid 108,336 7 % 280,865 22 % 389,201 14 % Managed Care (HMO and PPOs) 432,695 29 % 293,124 23 % 725,819 27 % UK Revenue 0 0 % 136,622 11 % 136,622 5 % Other patient revenue and adjustments, net 78,196 5 % 121,135 10 % 199,331 7 % Other non-patient revenue (a) 269,746 18 % 106,737 8 % 3,125 379,608 14 % Total Net Revenue $ 1,467,506 100 % $ 1,259,123 100 % $ 3,125 2,729,754 100 % For the six months ended June 30, 2020 Acute Care Behavioral Health Other Total Medicare $ 590,335 20 % $ 226,188 9 % $ 816,523 15 % Managed Medicare 404,762 14 % 119,217 5 % 523,979 9 % Medicaid 259,411 9 % 329,108 13 % 588,519 11 % Managed Medicaid 231,791 8 % 583,422 23 % 815,213 15 % Managed Care (HMO and PPOs) 973,432 33 % 633,811 25 % 1,607,243 29 % UK Revenue 0 0 % 273,472 11 % 273,472 5 % Other patient revenue and adjustments, net 142,795 5 % 244,195 10 % 386,990 7 % Other non-patient revenue (a) 386,029 13 % 155,819 6 % 5,634 547,482 10 % Total Net Revenue $ 2,988,555 100 % $ 2,565,232 100 % $ 5,634 5,559,421 100 % For the three months ended June 30, 2019 Acute Care Behavioral Health Other Total Medicare $ 319,060 21 % $ 139,248 11 % $ 458,308 16 % Managed Medicare 211,660 14 % 54,152 4 % 265,812 9 % Medicaid 138,682 9 % 183,563 14 % 322,245 11 % Managed Medicaid 145,970 10 % 275,252 21 % 421,222 15 % Managed Care (HMO and PPOs) 566,165 37 % 346,717 26 % 912,882 32 % UK Revenue 0 0 % 143,800 11 % 143,800 5 % Other patient revenue and adjustments, net 36,161 2 % 126,903 10 % 163,064 6 % Other non-patient revenue 114,011 7 % 50,606 4 % 3,218 167,835 6 % Total Net Revenue $ 1,531,709 100 % $ 1,320,241 100 % $ 3,218 2,855,168 100 % For the six months ended June 30, 2019 Acute Care Behavioral Health Other Total Medicare $ 654,969 21 % $ 276,704 11 % $ 931,673 16 % Managed Medicare 420,763 14 % 106,411 4 % 527,174 9 % Medicaid 243,192 8 % 356,479 14 % 599,671 11 % Managed Medicaid 279,701 9 % 542,525 21 % 822,226 15 % Managed Care (HMO and PPOs) 1,136,548 37 % 694,599 27 % 1,831,147 32 % UK Revenue 0 0 % 280,502 11 % 280,502 5 % Other patient revenue and adjustments, net 88,044 3 % 250,381 10 % 338,425 6 % Other non-patient revenue 223,336 7 % 99,023 4 % 6,382 328,741 6 % Total Net Revenue $ 3,046,553 100 % $ 2,606,624 100 % $ 6,382 5,659,559 100 % (a) Includes $157 million in Acute Care and $61 million in Behavioral Health of governmental stimulus program revenues in each of the three and six-months periods ended June 30, 2020.

Lease Accounting

Lease Accounting	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Lease Accounting	(13) Lease Accounting Our operating leases are primarily for real estate, including certain acute care facilities, off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. Our real estate lease agreements typically have initial terms of five to 10 years. These real estate leases may include one or more options to renew, with renewals that can extend the lease term from five to 10 years. The exercise of lease renewal options is at our sole discretion. When determining the lease term, we included options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Three of our hospital facilities are held under operating leases with Universal Health Realty Income Trust with two hospital terms expiring in 2021 and the third expiring in 2026 (see Note 2 for additional disclosure). We are also the lessee of the real property of certain facilities. Supplemental cash flow information related to leases for the six month periods ended June 30, 2020 and 2019 are as follows (in thousands): Six months ended June 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 56,102 $ 52,036 Operating cash flows from finance leases $ 966 $ 1,108 Financing cash flows from finance leases $ 1,267 $ 907 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 37,780 $ 359,329 Included in the $359 million of right-of-use assets obtained in exchange for operating lease obligations is $8.9 million new operating leases entered into during the six month period ended June 30, 2019.

Recent Accounting Standards

Recent Accounting Standards	6 Months Ended
	Jun. 30, 2020
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Standards	(14) Recent Accounting Standards In June 2016, the FASB issued ASU 2016-13, "Financial Instruments - Credit Losses," which introduced new guidance for an approach based on expected losses to estimate credit losses on certain types of financial instruments. Instruments in scope include loans, held-to-maturity debt securities, and net investments in leases as well as reinsurance and trade receivables. In November 2018, the FASB issued ASU 2018-19, which clarifies that operating lease receivables are outside the scope of the new standard. The standard will be effective for us in fiscal years beginning after December 15, 2019. The adoption of this guidance did not have a material impact on our consolidated financial statements. In January, 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment” (“ASU 2017-04”), which removes the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for the annual and interim periods beginning January 1, 2020 with early adoption permitted, and applied prospectively. The adoption of this guidance did not have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles- Goodwill and Other- Internal Use Software (Topic 350): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract, ("ASU 2018-15"), which requires customers in a cloud computing arrangement (i.e., hosting arrangement) that is a service contract to follow the internal use software guidance in ASC 350-40 to determine which implementation costs to capitalize or expense. ASU 2018-15 was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The adoption of this guidance did not have a material impact on our consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on our results of operations, cash flows or financial position.

Relationship with Universal H_2

Relationship with Universal Health Realty Income Trust and Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Remaining Renewal Options and Terms for Each of Three Hospital Facilities Leased from Trust	The table below details the renewal options and terms for each of our three acute care hospital facilities leased from the Trust: Hospital Name Annual Minimum Rent End of Lease Term Renewal Term (years) McAllen Medical Center $ 5,485,000 December, 2026 5(a) Wellington Regional Medical Center $ 3,030,000 December, 2021 10(b) Southwest Healthcare System, Inland Valley Campus $ 2,648,000 December, 2021 10(b) (a) We have one (b) We have two 5-year

Treasury (Tables)

Treasury (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Summary of Effects of Interest Rate Swap Agreements and Foreign Currency Foreign Exchange Contracts on Result of Operations	The following table presents the effects of our interest rate swap agreements and our foreign currency foreign exchange contracts on our results of operations for the three and six-month periods ended June 30, 2020 and 2019 (in thousands): Gain/(Loss) recognized in AOCI Three months ended Six months ended June 30, June 30, June 30, June 30, 2020 2019 2020 2019 Cash Flow Hedge relationships Interest rate swap agreements (a) $ 0 $ (1,008 ) $ 0 $ (3,925 ) Net Investment Hedge relationships Foreign currency foreign exchange contracts $ 2,989 $ 40,436 $ 43,535 $ 45,657 (a) The amount of gain reclassified out of AOCI into interest expense, net was $0 and $456,000 during the three-month periods ended June 30, 2020 and 2019, respectively, and $0 and $3.4 million during the six-month periods ended June 30, 2020 and 2019, respectively.
Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows	Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follow (in thousands): June 30, December 31, 2020 2019 Cash and cash equivalents $ 539,622 $ 61,268 Restricted cash and cash equivalents (a) 44,650 44,399 Total cash, cash equivalents and restricted cash $ 584,272 (b) $ 105,667 (a) Restricted cash and cash equivalents is included in other assets on the accompanying consolidated balance sheet. (b) Consists primarily of short-term cash accounts on which interest is being earned at various annual rates ranging from 0.10% to 0.65%.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis	The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) June 30, 2020 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds $ 174,200 Cash and cash equivalents 174,200 Term Deposit 100,000 Cash and cash equivalents 100,000 Money market mutual funds 60,870 Other assets 60,870 Certificates of deposit 2,201 Other assets 2,201 Available for sale securities 63,780 Other assets 63,780 Deferred compensation assets 31,292 Other assets 31,292 Foreign currency exchange contracts 2,187 Other current assets 2,187 $ 434,530 332,343 102,187 - Liabilities: Deferred compensation liability 31,292 Other noncurrent liabilities 31,292 $ 31,292 31,292 - - Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) December 31, 2019 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds $ 60,175 Other assets 60,175 Certificates of deposit 2,200 Other assets 2,200 Available for sale securities 70,478 Other assets 70,478 Deferred compensation assets 35,510 Other assets 35,510 Foreign currency exchange contracts 10,343 Other current assets 10,343 $ 178,706 168,363 10,343 - Liabilities: Deferred compensation liability $ 35,510 Other noncurrent liabilities 35,510 $ 35,510 35,510 - -

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	Three months ended June 30, 2020 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 6,736,777 $ 2,285,359 $ - $ 9,022,136 Gross outpatient revenues $ 3,394,680 $ 216,174 $ - $ 3,610,854 Total net revenues $ 1,467,506 $ 1,259,123 $ 3,125 $ 2,729,754 Income/(loss) before allocation of corporate overhead and income taxes $ 182,996 $ 256,766 $ (104,104 ) $ 335,658 Allocation of corporate overhead $ (55,983 ) $ (42,750 ) $ 98,733 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 127,013 $ 214,016 $ (5,371 ) $ 335,658 Total assets as of June 30, 2020 $ 4,467,698 $ 6,819,694 $ 861,107 $ 12,148,499 Six months ended June 30, 2020 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 14,558,249 $ 4,810,898 $ 0 $ 19,369,147 Gross outpatient revenues $ 8,076,421 $ 475,913 $ 0 $ 8,552,334 Total net revenues $ 2,988,555 $ 2,565,232 $ 5,634 $ 5,559,421 Income/(loss) before allocation of corporate overhead and income taxes $ 286,533 $ 494,449 $ (254,541 ) $ 526,441 Allocation of corporate overhead $ (111,956 ) $ (85,480 ) $ 197,436 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 174,577 $ 408,969 $ (57,105 ) $ 526,441 Total assets as of June 30, 2020 $ 4,467,698 $ 6,819,694 $ 861,107 $ 12,148,499 Three months ended June 30, 2019 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 7,051,925 $ 2,547,626 $ 0 $ 9,599,551 Gross outpatient revenues $ 4,402,308 $ 268,693 $ 0 $ 4,671,001 Total net revenues $ 1,531,709 $ 1,320,241 $ 3,218 $ 2,855,168 Income/(loss) before allocation of corporate overhead and income taxes $ 188,157 $ 265,986 $ (143,335 ) $ 310,808 Allocation of corporate overhead $ (57,528 ) $ (41,638 ) $ 99,166 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 130,629 $ 224,348 $ (44,169 ) $ 310,808 Total assets as of June 30, 2019 $ 4,413,509 $ 6,933,825 $ 405,316 $ 11,752,650 Six months ended June 30, 2019 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 14,215,639 $ 5,031,625 $ 0 $ 19,247,264 Gross outpatient revenues $ 8,659,922 $ 535,239 $ 0 $ 9,195,161 Total net revenues $ 3,046,553 $ 2,606,624 $ 6,382 $ 5,659,559 Income/(loss) before allocation of corporate overhead and income taxes $ 380,370 $ 510,154 $ (283,420 ) $ 607,104 Allocation of corporate overhead $ (115,028 ) $ (83,285 ) $ 198,313 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 265,342 $ 426,869 $ (85,107 ) $ 607,104 Total assets as of June 30, 2019 $ 4,413,509 $ 6,933,825 $ 405,316 $ 11,752,650 (a) Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $136 million and $144 million for the three-month periods ended June 30, 2020 and 2019, respectively, and approximately $273 million and $281 million for the six-month periods ended June 30, 2020 and 2019, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.192 billion and $1.217 billion as of June 30, 2020 and 2019, respectively.

Earnings Per Share Data ("EPS_2

Earnings Per Share Data ("EPS") and Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Computation of Basic and Diluted Earnings per Share	The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Three months ended June 30, Six months ended June 30, 2020 2019 2020 2019 Basic and Diluted: Net income attributable to UHS $ 251,929 $ 238,320 $ 393,966 $ 472,488 Less: Net income attributable to unvested restricted share grants (824 ) (656 ) (1,197 ) (1,171 ) Net income attributable to UHS – basic and diluted $ 251,105 $ 237,664 $ 392,769 $ 471,317 Weighted average number of common shares - basic 84,632 89,136 85,422 89,956 Net effect of dilutive stock options and grants based on the treasury stock method 427 99 335 145 Weighted average number of common shares and equivalents - diluted 85,059 89,235 85,757 90,101 Earnings per basic share attributable to UHS: $ 2.97 $ 2.67 $ 4.60 $ 5.24 Earnings per diluted share attributable to UHS: $ 2.95 $ 2.66 $ 4.58 $ 5.23

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Schedule of Disaggregates Revenue by Major Source	The following table disaggregates our revenue by major source for the three and six month periods ended June 30, 2020 and 2019 (in thousands): For the three months ended June 30, 2020 Acute Care Behavioral Health Other Total Medicare $ 264,310 18 % $ 106,571 8 % $ 370,881 14 % Managed Medicare 182,771 12 % 59,979 5 % 242,750 9 % Medicaid 131,452 9 % 154,090 12 % 285,542 10 % Managed Medicaid 108,336 7 % 280,865 22 % 389,201 14 % Managed Care (HMO and PPOs) 432,695 29 % 293,124 23 % 725,819 27 % UK Revenue 0 0 % 136,622 11 % 136,622 5 % Other patient revenue and adjustments, net 78,196 5 % 121,135 10 % 199,331 7 % Other non-patient revenue (a) 269,746 18 % 106,737 8 % 3,125 379,608 14 % Total Net Revenue $ 1,467,506 100 % $ 1,259,123 100 % $ 3,125 2,729,754 100 % For the six months ended June 30, 2020 Acute Care Behavioral Health Other Total Medicare $ 590,335 20 % $ 226,188 9 % $ 816,523 15 % Managed Medicare 404,762 14 % 119,217 5 % 523,979 9 % Medicaid 259,411 9 % 329,108 13 % 588,519 11 % Managed Medicaid 231,791 8 % 583,422 23 % 815,213 15 % Managed Care (HMO and PPOs) 973,432 33 % 633,811 25 % 1,607,243 29 % UK Revenue 0 0 % 273,472 11 % 273,472 5 % Other patient revenue and adjustments, net 142,795 5 % 244,195 10 % 386,990 7 % Other non-patient revenue (a) 386,029 13 % 155,819 6 % 5,634 547,482 10 % Total Net Revenue $ 2,988,555 100 % $ 2,565,232 100 % $ 5,634 5,559,421 100 % For the three months ended June 30, 2019 Acute Care Behavioral Health Other Total Medicare $ 319,060 21 % $ 139,248 11 % $ 458,308 16 % Managed Medicare 211,660 14 % 54,152 4 % 265,812 9 % Medicaid 138,682 9 % 183,563 14 % 322,245 11 % Managed Medicaid 145,970 10 % 275,252 21 % 421,222 15 % Managed Care (HMO and PPOs) 566,165 37 % 346,717 26 % 912,882 32 % UK Revenue 0 0 % 143,800 11 % 143,800 5 % Other patient revenue and adjustments, net 36,161 2 % 126,903 10 % 163,064 6 % Other non-patient revenue 114,011 7 % 50,606 4 % 3,218 167,835 6 % Total Net Revenue $ 1,531,709 100 % $ 1,320,241 100 % $ 3,218 2,855,168 100 % For the six months ended June 30, 2019 Acute Care Behavioral Health Other Total Medicare $ 654,969 21 % $ 276,704 11 % $ 931,673 16 % Managed Medicare 420,763 14 % 106,411 4 % 527,174 9 % Medicaid 243,192 8 % 356,479 14 % 599,671 11 % Managed Medicaid 279,701 9 % 542,525 21 % 822,226 15 % Managed Care (HMO and PPOs) 1,136,548 37 % 694,599 27 % 1,831,147 32 % UK Revenue 0 0 % 280,502 11 % 280,502 5 % Other patient revenue and adjustments, net 88,044 3 % 250,381 10 % 338,425 6 % Other non-patient revenue 223,336 7 % 99,023 4 % 6,382 328,741 6 % Total Net Revenue $ 3,046,553 100 % $ 2,606,624 100 % $ 6,382 5,659,559 100 % (a) Includes $157 million in Acute Care and $61 million in Behavioral Health of governmental stimulus program revenues in each of the three and six-months periods ended June 30, 2020.

Lease Accounting (Tables)

Lease Accounting (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases for the six month periods ended June 30, 2020 and 2019 are as follows (in thousands): Six months ended June 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 56,102 $ 52,036 Operating cash flows from finance leases $ 966 $ 1,108 Financing cash flows from finance leases $ 1,267 $ 907 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 37,780 $ 359,329

Relationship with Universal H_3

Relationship with Universal Health Realty Income Trust and Related Party Transactions - Additional Information (Detail)	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)Facility	Dec. 31, 2019USD ($)	Sep. 30, 2019SquareFoot	Jun. 30, 2019USD ($)	Dec. 31, 2013	Jun. 30, 2020USD ($)HospitalFacilitySquareFootBedLease	Jun. 30, 2019USD ($)Hospital	Dec. 31, 2019USD ($)	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Net revenues	$ 2,729,754,000			$ 2,855,168,000		$ 5,559,421,000	$ 5,659,559,000
Number of hospital facilities | Hospital						3
Number of third party tenant rentable square feet | SquareFoot						26,000
Number of flex lease commitment rentable square feet | SquareFoot						20,000
Chief Executive Officer
Related Party Transaction [Line Items]
Estimated payments to acquire life insurance policies						$ 28,000,000
Payments to acquire life insurance policies, net						1,100,000		$ 1,100,000
Chief Executive Officer | Trust Owned by CEO
Related Party Transaction [Line Items]
Estimated payments to acquire life insurance policies						$ 9,000,000
Joint Venture Agreement
Related Party Transaction [Line Items]
Lease initial terms	20 years					20 years
Lease renewal period, years						10 years
Number of beds | Bed						108
Number of triple net lease | Lease						5
Number of square foot to be constructed | SquareFoot						80,000
Expected aggregate fee						$ 750,000
Estimated project cost						37,500,000
Estimated initial annual rent						$ 2,700,000
Expected project to begin and be completed year						2020
Minimum
Related Party Transaction [Line Items]
Lease initial terms	5 years					5 years
Minimum | Chief Executive Officer
Related Party Transaction [Line Items]
Estimated death benefit proceeds						$ 37,000,000
Maximum
Related Party Transaction [Line Items]
Lease initial terms	10 years					10 years
Maximum | Joint Venture Agreement
Related Party Transaction [Line Items]
Expected project to begin and be completed year						2021
Relationship with Universal Health Realty Income Trust
Related Party Transaction [Line Items]
Trust outstanding shares held, percentage	5.70%					5.70%
Percentage of advisory fee on average invested real estate assets	0.70%			0.70%		0.70%	0.70%	0.70%	0.70%	0.70%
Pre-tax share of income from the Trust	$ 200,000			$ 200,000		$ 500,000	$ 500,000
Dividends received from the Trust	543,000			536,000		1,100,000	1,100,000
Carrying value of investment in Trust	5,900,000	$ 6,400,000				5,900,000		$ 6,400,000
Market value of investment in Trust	$ 62,600,000	92,400,000				$ 62,600,000		$ 92,400,000
Lease initial terms	10 years					10 years
Lease renewal period, years						5 years
Rent expense under operating leases	$ 4,000,000			8,000,000		$ 4,000,000	$ 8,000,000
Notice period on renewal of lease						90 days
Period of rights of refusal to leased facilities						180 days
Number of hospital facilities | Hospital						3	3
Number of free-standing emergency departments to be acquired | Facility	2					2
Number of square feet to be constructed | SquareFoot			75,000
Percentage of master lease rentable square feet						50.00%
Annual Minimum Rent						$ 644,000
Relationship with Universal Health Realty Income Trust | Minimum
Related Party Transaction [Line Items]
Lease initial terms	13 years					13 years
Relationship with Universal Health Realty Income Trust | Minimum | Limited Liability Companies
Related Party Transaction [Line Items]
Non-controlling ownership interests by subsidiaries	95.00%					95.00%
Relationship with Universal Health Realty Income Trust | Maximum
Related Party Transaction [Line Items]
Lease initial terms	15 years					15 years
Relationship with Universal Health Realty Income Trust | Maximum | Limited Liability Companies
Related Party Transaction [Line Items]
Non-controlling ownership interests by subsidiaries	100.00%					100.00%
Relationship with Universal Health Realty Income Trust | Advisory Fee
Related Party Transaction [Line Items]
Net revenues	$ 1,000,000			$ 2,000,000		$ 1,000,000	$ 2,000,000
Premier, Inc. | Other (Income) Expense, Net | ASU 2016-01
Related Party Transaction [Line Items]
Unrealized gain						6,000,000
Premier, Inc. | Group Purchasing Organization Agreement | Restricted Stock
Related Party Transaction [Line Items]
Shares vesting period					7 years
Shares vesting period start year					2014
Shares vesting period end year					2020
Market value of retained vested shares		$ 70,000,000				$ 64,000,000

Remaining Renewal Options and T

Remaining Renewal Options and Terms for Hospital Facilities Leased from Trust (Detail)	6 Months Ended
	Jun. 30, 2020USD ($)
McAllen Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Annual Minimum Rent	$ 5,485,000
End of Lease Term	2026-12
Renewal Term (years)	5 years	[1]
Wellington Regional Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Annual Minimum Rent	$ 3,030,000
End of Lease Term	2021-12
Renewal Term (years)	10 years	[2]
Southwest Healthcare System, Inland Valley Campus
Property Subject to or Available for Operating Lease [Line Items]
Annual Minimum Rent	$ 2,648,000
End of Lease Term	2021-12
Renewal Term (years)	10 years	[2]
[1]	We have one
[2]	We have two 5-year

Remaining Renewal Options and_2

Remaining Renewal Options and Terms for Hospital Facilities Leased from Trust (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2020RenewalOption
McAllen Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Number of renewal options at existing lease rates	1
Renewal options term at existing lease rates	5 years
McAllen Medical Center | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at existing lease rates expiration year	2031
Wellington Regional Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Number of renewal options at fair market lease rates	2
Renewal options term at fair market lease rates	5 years
Wellington Regional Medical Center | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2031
Wellington Regional Medical Center | Minimum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2022
Southwest Healthcare System, Inland Valley Campus
Property Subject to or Available for Operating Lease [Line Items]
Number of renewal options at fair market lease rates	2
Renewal options term at fair market lease rates	5 years
Southwest Healthcare System, Inland Valley Campus | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2031
Southwest Healthcare System, Inland Valley Campus | Minimum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2022

Other Noncurrent Liabilities _2

Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail) $ in Millions	Jun. 30, 2020USD ($)Facility
Minority Interest [Line Items]
Behavioral health care facilities with outside owners holding non-controlling minority interest | Facility	3
Non-controlling interest balances	$ 73
Redeemable non-controlling interest balances	$ 4
Outside Owners | Acute Care Facility | Washington, District of Columbia
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	20.00%
Outside Owners | Acute Care Facility | Texas
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	11.00%
Outside Owners | Acute Care Facility | Nevada
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	5.00%
Outside Owners | Behavioral Health Care Facility | Pennsylvania
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	20.00%
Outside Owners | Behavioral Health Care Facility | Ohio
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	30.00%
Outside Owners | Behavioral Health Care Facility | Washington
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	20.00%

Treasury - Additional Informati

Treasury - Additional Information (Detail)

Nov. 26, 2018USD ($)

Oct. 23, 2018USD ($)

Jun. 07, 2016USD ($)

Jun. 30, 2020USD ($)

Jun. 30, 2019USD ($)

Dec. 31, 2015USD ($)Derivative

Dec. 31, 2019USD ($)

Oct. 31, 2018USD ($)

Jun. 30, 2018USD ($)

Apr. 30, 2018USD ($)

Jun. 03, 2016USD ($)

Aug. 07, 2014USD ($)

Equity Class Of Treasury Stock [Line Items]

Line of credit facility, starting date

Oct. 23, 2018

Rate adjustment to weighted average federal funds rate for credit facility borrowings

0.50%

Rate adjustment to one month Eurodollar rate on credit facility borrowings

1.00%

Accounts receivable securitization program credit facility, borrowing capacity

$ 440,000,000

$ 450,000,000

Accounts receivable securitization program credit facility, amount outstanding

$ 0

Accounts receivable securitization program credit facility, available borrowing capacity

378,000,000

Debt instrument carrying amount

3,500,000,000

$ 4,000,000,000

Fair value of debt

3,500,000,000

$ 4,000,000,000

One Point Three One Percent Forward Starting Interest Rate Swaps

Equity Class Of Treasury Stock [Line Items]

Number of additional forward starting interest rate swaps | Derivative

9

Maturity date of interest rate cash flow hedges

Apr. 15, 2019

Fixed rate payable on interest rate swap

1.31%

Foreign Currency Forward Exchange Contracts

Equity Class Of Treasury Stock [Line Items]

Net cash (outflows) inflows

$ 57,000,000

$ 5,000,000

Cash Flow Hedging | One Point Three One Percent Forward Starting Interest Rate Swaps

Equity Class Of Treasury Stock [Line Items]

Notional amount of interest rate cash flow hedges

$ 1,000,000,000

Tranche B Term Loan | One Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

0.75%

Tranche B Term Loan | One Two Three Six Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

1.75%

Revolving Credit Facility

Equity Class Of Treasury Stock [Line Items]

Line of credit facility, borrowing capacity

$ 1,000,000,000

$ 800,000,000

Line of credit facility increased amount

$ 200,000,000

Credit facility, maturity date

Oct. 23, 2023

Aug. 7, 2019

Line of credit facility, available borrowing capacity

$ 997,000,000

Line of credit facility amount outstanding

$ 1,000,000,000

$ 0

Current applicable margins

1.375%

Revolving Credit Facility | ABR-based loans

Equity Class Of Treasury Stock [Line Items]

Current applicable margins

1.75%

Revolving Credit Facility | Minimum | One Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

0.375%

Revolving Credit Facility | Minimum | One Two Three Six Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

1.375%

Revolving Credit Facility | Maximum | One Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

0.625%

Revolving Credit Facility | Maximum | One Two Three Six Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

1.625%

Revolving Credit Facility | Letter of Credit

Equity Class Of Treasury Stock [Line Items]

Line of credit facility, borrowing capacity

$ 125,000,000

Letters of credit, outstanding

3,000,000

Tranche A Term Loan

Equity Class Of Treasury Stock [Line Items]

Line of credit facility, borrowing capacity

2,000,000,000

$ 1,710,000,000

Line of credit facility increased amount

$ 290,000,000

Senior notes, maturity date

Oct. 23, 2023

Aug. 7, 2019

Line of credit facility amount outstanding

$ 1,925,000,000

Tranche A Term Loan | Quarterly Payment for First Eight Installments

Equity Class Of Treasury Stock [Line Items]

Scheduled principal payments per quarter

$ 12,500,000

Debt instrument payment, description

commenced in March of 2019 and are scheduled to continue through December of 2020.

Tranche A Term Loan | Quarterly Payment after Eight Installments Until Maturity

Equity Class Of Treasury Stock [Line Items]

Scheduled principal payments per quarter

25,000,000

Debt instrument payment, description

commencing in March of 2021 until maturity in October of 2023

Tranche B Term Loan

Equity Class Of Treasury Stock [Line Items]

Line of credit facility, borrowing capacity

$ 500,000,000

Senior notes, maturity date

Oct. 31, 2025

Line of credit facility amount outstanding

$ 493,000,000

Scheduled principal payments per quarter

$ 1,250,000

Debt instrument payment, description

commenced on March 31, 2019 and are scheduled to continue until maturity in October of 2025

New Senior Secured Notes

Equity Class Of Treasury Stock [Line Items]

Senior notes, issued

$ 1,100,000,000

New Senior Secured Notes | 3.75% Senior Secured Notes due 2019

Equity Class Of Treasury Stock [Line Items]

Senior Notes

$ 300,000,000

Senior notes, interest rate

3.75%

3.75%

Senior notes, issued

$ 300,000,000

Redemption price, percentage

100.485%

Redemption premium paid

$ 1,000,000

New Senior Secured Notes | 4.75% Senior Secured Notes due 2022

Equity Class Of Treasury Stock [Line Items]

Senior notes, maturity date

Aug. 1, 2022

Senior notes, interest rate

4.75%

Senior notes, issued

$ 700,000,000

$ 400,000,000

$ 300,000,000

Senior notes issued percentage

101.50%

Senior notes yield percentage

4.35%

New Senior Secured Notes | 5.00% Senior Secured Notes due 2026

Equity Class Of Treasury Stock [Line Items]

Senior notes, maturity date

Jun. 1, 2026

Senior notes, interest rate

5.00%

Senior notes, issued

$ 400,000,000

Term Loan A

Equity Class Of Treasury Stock [Line Items]

Current applicable margins

1.375%

Term Loan A | ABR-based loans

Equity Class Of Treasury Stock [Line Items]

Current applicable margins

0.375%

Term Loan A | Minimum | One Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

0.375%

Term Loan A | Minimum | One Two Three Six Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

1.375%

Term Loan A | Maximum | One Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

0.625%

Term Loan A | Maximum | One Two Three Six Month LIBOR Rate Plus Index Based Loans

Equity Class Of Treasury Stock [Line Items]

Consolidated Leverage Ratio

1.625%

Summary of Effects of Interest

Summary of Effects of Interest Rate Swap Agreements and Foreign Currency Foreign Exchange Contracts on Result of Operations (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative Instruments Gain Loss [Line Items]
Gain/(Loss) recognized in AOCI			$ (1,008)		$ (3,925)
Designated As Hedging Instrument | Cash Flow Hedging | Interest Rate Swap
Derivative Instruments Gain Loss [Line Items]
Gain/(Loss) recognized in AOCI	[1]	$ 0	(1,008)	$ 0	(3,925)
Designated As Hedging Instrument | Net Investment Hedge | Foreign Currency Foreign Exchange Contracts
Derivative Instruments Gain Loss [Line Items]
Gain/(Loss) recognized in AOCI		$ 2,989	$ 40,436	$ 43,535	$ 45,657
[1]	The amount of gain reclassified out of AOCI into interest expense, net was $0 and $456,000 during the three-month periods ended June 30, 2020 and 2019, respectively, and $0 and $3.4 million during the six-month periods ended June 30, 2020 and 2019, respectively.

Summary of Effects of Interes_2

Summary of Effects of Interest Rate Swap Agreements and Foreign Currency Foreign Exchange Contracts on Result of Operations (Parenthetical) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Interest Expense, Net | Designated As Hedging Instrument | Cash Flow Hedging | Interest Rate Swap
Derivative Instruments Gain Loss [Line Items]
Gain reclassified out of AOCI into interest expenses	$ 0	$ 456,000	$ 0	$ 3,400,000

Summary of Cash, Cash Equivalen

Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands		Jun. 30, 2020		Dec. 31, 2019
Cash And Cash Equivalents Period Increase Decrease [Abstract]
Cash and cash equivalents		$ 539,622		$ 61,268
Restricted cash and cash equivalents	[1]	$ 44,650		$ 44,399
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]		us-gaap:OtherAssetsMiscellaneousNoncurrent		us-gaap:OtherAssetsMiscellaneousNoncurrent
Total cash, cash equivalents and restricted cash		$ 584,272	[2]	$ 105,667
[1]	Restricted cash and cash equivalents is included in other assets on the accompanying consolidated balance sheet.
[2]	Consists primarily of short-term cash accounts on which interest is being earned at various annual rates ranging from 0.10% to 0.65%.

Summary of Cash, Cash Equival_2

Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2020
Minimum
Cash And Cash Equivalents Period Increase Decrease [Line Items]
Short -term cash investments interest rate	0.10%
Maximum
Cash And Cash Equivalents Period Increase Decrease [Line Items]
Short -term cash investments interest rate	0.65%

Summary of Assets and Liabiliti

Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) - Recurring - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets:
Assets, fair value	$ 434,530	$ 178,706
Liabilities:
Liabilities, fair value	31,292	35,510
Money Market Mutual Funds | Cash and Cash Equivalents
Assets:
Assets, fair value	174,200
Money Market Mutual Funds | Other Assets
Assets:
Assets, fair value	60,870	60,175
Term Deposit | Cash and Cash Equivalents
Assets:
Assets, fair value	100,000
Certificates of Deposit | Other Assets
Assets:
Assets, fair value	2,201	2,200
Available for Sale Securities | Other Assets
Assets:
Assets, fair value	63,780	70,478
Deferred Compensation Assets | Other Assets
Assets:
Assets, fair value	31,292	35,510
Foreign Currency Foreign Exchange Contracts | Other Current Assets
Assets:
Assets, fair value	2,187	10,343
Deferred Compensation Liability | Other Noncurrent Liabilities
Liabilities:
Liabilities, fair value	31,292	35,510
Basis of Fair Value Measurement, Level 1
Assets:
Assets, fair value	332,343	168,363
Liabilities:
Liabilities, fair value	31,292	35,510
Basis of Fair Value Measurement, Level 1 | Money Market Mutual Funds | Cash and Cash Equivalents
Assets:
Assets, fair value	174,200
Basis of Fair Value Measurement, Level 1 | Money Market Mutual Funds | Other Assets
Assets:
Assets, fair value	60,870	60,175
Basis of Fair Value Measurement, Level 1 | Certificates of Deposit | Other Assets
Assets:
Assets, fair value	2,201	2,200
Basis of Fair Value Measurement, Level 1 | Available for Sale Securities | Other Assets
Assets:
Assets, fair value	63,780	70,478
Basis of Fair Value Measurement, Level 1 | Deferred Compensation Assets | Other Assets
Assets:
Assets, fair value	31,292	35,510
Basis of Fair Value Measurement, Level 1 | Deferred Compensation Liability | Other Noncurrent Liabilities
Liabilities:
Liabilities, fair value	31,292	35,510
Basis of Fair Value Measurement, Level 2
Assets:
Assets, fair value	102,187	10,343
Basis of Fair Value Measurement, Level 2 | Term Deposit | Cash and Cash Equivalents
Assets:
Assets, fair value	100,000
Basis of Fair Value Measurement, Level 2 | Foreign Currency Foreign Exchange Contracts | Other Current Assets
Assets:
Assets, fair value	$ 2,187	$ 10,343

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) £ in Millions

Jul. 09, 2020USD ($)

Jul. 31, 2019USD ($)

Jun. 30, 2020USD ($)

Jun. 30, 2020GBP (£)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2012USD ($)

Dec. 31, 2011USD ($)

Jun. 30, 2020GBP (£)

Jun. 01, 2020USD ($)

Mar. 31, 2020USD ($)

Jan. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability, current

$ 42,000,000

$ 42,000,000

Compensation liability claims

90,000,000

81,000,000

Compensation and related benefits

40,000,000

40,000,000

Amount of remaining settlement agreements

6,000,000

Accrued interest on settlement amount

$ 230,000

Corporate integrity agreement

5 years

5 years

Department of Human Services

Commitments and Contingencies Disclosure [Line Items]

Aggregate payment made

$ 4,000,000

$ 4,000,000

$ 4,000,000

$ 4,000,000

$ 4,000,000

Amount claimed from over payments of legal settlements

7,000,000

8,000,000

7,000,000

$ 4,000,000

Amount claimed from over payments of legal settlements due to change in calculations

3,000,000

2,000,000

2,000,000

River Point Behavioral Health

Commitments and Contingencies Disclosure [Line Items]

Amount withheld in contingent Medicare payment suspension

$ 9,700,000

Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Aggregate payment made

$ 117,300,000

DOJ

Commitments and Contingencies Disclosure [Line Items]

Definitive settlement and related civil agreements

$ 127,000,000

Pre-tax reserve

$ 134,000,000

134,000,000

DOJ | Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Aggregate payment made

88,100,000

US District Court for District Of Massachusetts | Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Aggregate payment made

10,000,000

Per Occurrence/Per Location Deductible | Wind Storms

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

$ 2,500,000

OTHER STATES | Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Aggregate payment made

$ 28,900,000

Cygnet Health Care Limited

Commitments and Contingencies Disclosure [Line Items]

Property insurance | £

£ 1,500

Maximum

Commitments and Contingencies Disclosure [Line Items]

Percentage of accrued interest on the settlement amounts

1.25%

1.25%

Maximum | Wind Storms

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

$ 1,000,000,000

Percentage of insurance deductible

5.00%

5.00%

Maximum | Flood

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

$ 100,000,000

Maximum | LAS VEGAS, NEVADA | Earthquake

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

500,000,000

Maximum | CALIFORNIA | Earthquake

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

130,000,000

Maximum | Faulty Zones of UNITED STATES | Earthquake

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

100,000,000

Maximum | PUERTO RICO | Earthquake

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

40,000,000

Maximum | PUERTO RICO | Flood

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

1,000,000

Maximum | OTHER STATES | Earthquake

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

250,000,000

Maximum | Texas | Flood

Commitments and Contingencies Disclosure [Line Items]

Commercial property insurance policies covering catastrophic losses

$ 10,000,000

Minimum

Commitments and Contingencies Disclosure [Line Items]

Percentage of accrued interest on the settlement amounts

2.125%

2.125%

Minimum | Wind Storms

Commitments and Contingencies Disclosure [Line Items]

Percentage of insurance deductible

3.00%

3.00%

General And Professional Liability Insurance Policies

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability

$ 20,000,000

General and Professional Liability

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability

$ 250,000,000

242,000,000

Subsidiaries | Professional Liability

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability

5,000,000

$ 5,000,000

$ 5,000,000

Purchased several excess policies through commercial insurance carriers per occurrence

$ 2,500,000

Purchased several excess policies through commercial insurance carriers per occurrence excess claim amount

10,000,000

Subsidiaries | Professional Liability | Cygnet Health Care Limited

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability | £

£ 10

Subsidiaries | Professional Liability | Maximum

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability

10,000,000

$ 10,000,000

Subsidiaries | General Liability

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability

$ 3,000,000

$ 3,000,000

$ 3,000,000

Subsidiaries | General Liability | Cygnet Health Care Limited

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability | £

£ 25

Subsidiaries | General Liability | Maximum

Commitments and Contingencies Disclosure [Line Items]

Self-insured for professional and general liability

$ 3,000,000

$ 3,000,000

Subsidiaries | General And Professional Liability Insurance Policies

Commitments and Contingencies Disclosure [Line Items]

Percentage of liability for claims paid under commercially insured coverage

10.00%

10.00%

Subsidiaries | General And Professional Liability Insurance Policies | Maximum

Commitments and Contingencies Disclosure [Line Items]

Purchased several excess policies through commercial insurance carriers per occurrence

$ 250,000,000

$ 250,000,000

$ 200,000,000

Liability for claims paid under commercially insured coverage

$ 5,000,000

Subsidiaries | General And Professional Liability Insurance Policies | Maximum | Located in U.K.

Commitments and Contingencies Disclosure [Line Items]

Liability for claims paid under commercially insured coverage

$ 8,500,000

Segment Reporting (Detail)

Segment Reporting (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Gross inpatient revenues		$ 9,022,136	$ 9,599,551	$ 19,369,147	$ 19,247,264
Gross outpatient revenues		3,610,854	4,671,001	8,552,334	9,195,161
Total net revenues		2,729,754	2,855,168	5,559,421	5,659,559
Income/(loss) before allocation of corporate overhead and income taxes		335,658	310,808	526,441	607,104
Allocation of corporate overhead		0	0	0	0
Income before income taxes		335,658	310,808	526,441	607,104
Total assets		12,148,499	11,752,650	12,148,499	11,752,650	$ 11,668,250
Acute Care Hospital Services
Segment Reporting Information [Line Items]
Gross inpatient revenues		6,736,777	7,051,925	14,558,249	14,215,639
Gross outpatient revenues		3,394,680	4,402,308	8,076,421	8,659,922
Total net revenues		1,467,506	1,531,709	2,988,555	3,046,553
Income/(loss) before allocation of corporate overhead and income taxes		182,996	188,157	286,533	380,370
Allocation of corporate overhead		(55,983)	(57,528)	(111,956)	(115,028)
Income before income taxes		127,013	130,629	174,577	265,342
Total assets		4,467,698	4,413,509	4,467,698	4,413,509
Behavioral Health Services
Segment Reporting Information [Line Items]
Gross inpatient revenues	[1]	2,285,359	2,547,626	4,810,898	5,031,625
Gross outpatient revenues	[1]	216,174	268,693	475,913	535,239
Total net revenues	[1]	1,259,123	1,320,241	2,565,232	2,606,624
Income/(loss) before allocation of corporate overhead and income taxes	[1]	256,766	265,986	494,449	510,154
Allocation of corporate overhead	[1]	(42,750)	(41,638)	(85,480)	(83,285)
Income before income taxes	[1]	214,016	224,348	408,969	426,869
Total assets	[1]	6,819,694	6,933,825	6,819,694	6,933,825
Other
Segment Reporting Information [Line Items]
Gross inpatient revenues			0	0	0
Gross outpatient revenues			0	0	0
Total net revenues		3,125	3,218	5,634	6,382
Income/(loss) before allocation of corporate overhead and income taxes		(104,104)	(143,335)	(254,541)	(283,420)
Allocation of corporate overhead		98,733	99,166	197,436	198,313
Income before income taxes		(5,371)	(44,169)	(57,105)	(85,107)
Total assets		$ 861,107	$ 405,316	$ 861,107	$ 405,316
[1]	Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $136 million and $144 million for the three-month periods ended June 30, 2020 and 2019, respectively, and approximately $273 million and $281 million for the six-month periods ended June 30, 2020 and 2019, respectively.  Total assets at our U.K. behavioral health care facilities were approximately $1.192 billion and $1.217 billion as of June 30, 2020 and 2019, respectively.

Segment Reporting (Parenthetica

Segment Reporting (Parenthetical) (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net revenues		$ 2,729,754	$ 2,855,168	$ 5,559,421	$ 5,659,559
Total assets		12,148,499	11,752,650	12,148,499	11,752,650	$ 11,668,250
Behavioral Health Services
Segment Reporting Information [Line Items]
Net revenues	[1]	1,259,123	1,320,241	2,565,232	2,606,624
Total assets	[1]	6,819,694	6,933,825	6,819,694	6,933,825
Behavioral Health Services | Located in U.K.
Segment Reporting Information [Line Items]
Net revenues		136,000	273,000	144,000	281,000
Total assets		$ 1,192,000	$ 1,217,000	$ 1,192,000	$ 1,217,000
[1]	Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $136 million and $144 million for the three-month periods ended June 30, 2020 and 2019, respectively, and approximately $273 million and $281 million for the six-month periods ended June 30, 2020 and 2019, respectively.  Total assets at our U.K. behavioral health care facilities were approximately $1.192 billion and $1.217 billion as of June 30, 2020 and 2019, respectively.

Computation of Basic and Dilute

Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Basic and Diluted:
Net income attributable to UHS	$ 251,929	$ 238,320	$ 393,966	$ 472,488
Less: Net income attributable to unvested restricted share grants	(824)	(656)	(1,197)	(1,171)
Net income attributable to UHS – basic and diluted	$ 251,105	$ 237,664	$ 392,769	$ 471,317
Weighted average number of common shares - basic	84,632	89,136	85,422	89,956
Net effect of dilutive stock options and grants based on the treasury stock method	427	99	335	145
Weighted average number of common shares and equivalents - diluted	85,059	89,235	85,757	90,101
Earnings per basic share attributable to UHS:	$ 2.97	$ 2.67	$ 4.60	$ 5.24
Earnings per diluted share attributable to UHS:	$ 2.95	$ 2.66	$ 4.58	$ 5.23

Earnings Per Share Data ("EPS_3

Earnings Per Share Data ("EPS") and Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive weighted average stock options excluded from computation of earnings per share	7,100,000	8,500,000	6,500,000	7,800,000
Unrecognized compensation cost related to unvested options and restricted stock	$ 128,100		$ 128,100
Stock options granted during period			2,545,966
Weighted-average grant date fair value, per share			$ 14.25
Compensation cost recognized			$ 33,954	$ 34,676
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized, pre-tax charge	13,200	$ 14,700	28,600	30,500
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized, pre-tax charge	$ 2,400	$ 2,100	$ 4,700	$ 3,700
Unrecognized compensation cost vesting period			2 years 7 months 6 days
Restricted shares granted during period			125,467
Weighted-average grant date fair value, per share			$ 68.06
Unvested Stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost vesting period			2 years 7 months 6 days

Dispositions and Acquisitions -

Dispositions and Acquisitions - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Business Combinations [Abstract]
Acquisition, cash paid	$ 1,000,000	$ 0
Aggregate cash proceeds from divestiture of businesses	$ 6,000,000	$ 0

Dividends - Additional Informat

Dividends - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2019
Dividends [Abstract]
Dividends declared and paid	$ 17.3	$ 8.9	$ 18
Dividends declared and paid, per share	$ 0.20	$ 0.10

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jan. 01, 2020
Income Taxes [Line Items]
Effective income tax rate	23.60%	23.80%	22.40%	21.20%
Increase (decrease) in provision for income tax related to change in enacted tax law	$ 4,000,000		$ 4,000,000
Tax benefits from employee share-based payments			12,000,000
Increase in provision for income taxes			1,000,000	$ 15,000,000
Provisional deferred tax - GILTI			$ 0
Unrecognized tax benefits					$ 2,000,000
Impact of unrecognized tax benefits if recognized					$ 2,000,000
Period of expiration of the statute of limitations for certain jurisdictions				within the next twelve months
Jurisdictions statutes of limitations expiration period				12 months
Maximum
Income Taxes [Line Items]
Provisional deferred tax - GILTI				$ 1,000,000
Accrued interest and penalties		$ 1,000,000		$ 1,000,000
Foreign and U.S. state and local jurisdictions have statutes of limitations, in years				4 years
Minimum
Income Taxes [Line Items]
Foreign and U.S. state and local jurisdictions have statutes of limitations, in years				3 years

Schedule of Disaggregates Reven

Schedule of Disaggregates Revenue by Major Source (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Net revenues		$ 2,729,754	$ 2,855,168	$ 5,559,421	$ 5,659,559
Percentage of Net Revenue		100.00%	100.00%	100.00%	100.00%
Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 370,881	$ 458,308	$ 816,523	$ 931,673
Percentage of Net Revenue		14.00%	16.00%	15.00%	16.00%
Managed Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 242,750	$ 265,812	$ 523,979	$ 527,174
Percentage of Net Revenue		9.00%	9.00%	9.00%	9.00%
Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 285,542	$ 322,245	$ 588,519	$ 599,671
Percentage of Net Revenue		10.00%	11.00%	11.00%	11.00%
Managed Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 389,201	$ 421,222	$ 815,213	$ 822,226
Percentage of Net Revenue		14.00%	15.00%	15.00%	15.00%
Managed Care (HMO and PPOs)
Disaggregation Of Revenue [Line Items]
Net revenues		$ 725,819	$ 912,882	$ 1,607,243	$ 1,831,147
Percentage of Net Revenue		27.00%	32.00%	29.00%	32.00%
UK Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 136,622	$ 143,800	$ 273,472	$ 280,502
Percentage of Net Revenue		5.00%	5.00%	5.00%	5.00%
Other Patient Revenue and Adjustments, Net
Disaggregation Of Revenue [Line Items]
Net revenues		$ 199,331	$ 163,064	$ 386,990	$ 338,425
Percentage of Net Revenue		7.00%	6.00%	7.00%	6.00%
Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 379,608	$ 167,835	$ 547,482	$ 328,741
Percentage of Net Revenue		14.00%	6.00%	10.00%	6.00%
Acute Care Hospital Services
Disaggregation Of Revenue [Line Items]
Net revenues		$ 1,467,506	$ 1,531,709	$ 2,988,555	$ 3,046,553
Percentage of Net Revenue		100.00%	100.00%	100.00%	100.00%
Acute Care Hospital Services | Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 264,310	$ 319,060	$ 590,335	$ 654,969
Percentage of Net Revenue		18.00%	21.00%	20.00%	21.00%
Acute Care Hospital Services | Managed Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 182,771	$ 211,660	$ 404,762	$ 420,763
Percentage of Net Revenue		12.00%	14.00%	14.00%	14.00%
Acute Care Hospital Services | Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 131,452	$ 138,682	$ 259,411	$ 243,192
Percentage of Net Revenue		9.00%	9.00%	9.00%	8.00%
Acute Care Hospital Services | Managed Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 108,336	$ 145,970	$ 231,791	$ 279,701
Percentage of Net Revenue		7.00%	10.00%	8.00%	9.00%
Acute Care Hospital Services | Managed Care (HMO and PPOs)
Disaggregation Of Revenue [Line Items]
Net revenues		$ 432,695	$ 566,165	$ 973,432	$ 1,136,548
Percentage of Net Revenue		29.00%	37.00%	33.00%	37.00%
Acute Care Hospital Services | UK Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 0	$ 0	$ 0	$ 0
Percentage of Net Revenue		0.00%	0.00%	0.00%	0.00%
Acute Care Hospital Services | Other Patient Revenue and Adjustments, Net
Disaggregation Of Revenue [Line Items]
Net revenues		$ 78,196	$ 36,161	$ 142,795	$ 88,044
Percentage of Net Revenue		5.00%	2.00%	5.00%	3.00%
Acute Care Hospital Services | Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 269,746	$ 114,011	$ 386,029	$ 223,336
Percentage of Net Revenue		18.00%	7.00%	13.00%	7.00%
Behavioral Health Services
Disaggregation Of Revenue [Line Items]
Net revenues	[1]	$ 1,259,123	$ 1,320,241	$ 2,565,232	$ 2,606,624
Percentage of Net Revenue		100.00%	100.00%	100.00%	100.00%
Behavioral Health Services | Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 106,571	$ 139,248	$ 226,188	$ 276,704
Percentage of Net Revenue		8.00%	11.00%	9.00%	11.00%
Behavioral Health Services | Managed Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 59,979	$ 54,152	$ 119,217	$ 106,411
Percentage of Net Revenue		5.00%	4.00%	5.00%	4.00%
Behavioral Health Services | Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 154,090	$ 183,563	$ 329,108	$ 356,479
Percentage of Net Revenue		12.00%	14.00%	13.00%	14.00%
Behavioral Health Services | Managed Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 280,865	$ 275,252	$ 583,422	$ 542,525
Percentage of Net Revenue		22.00%	21.00%	23.00%	21.00%
Behavioral Health Services | Managed Care (HMO and PPOs)
Disaggregation Of Revenue [Line Items]
Net revenues		$ 293,124	$ 346,717	$ 633,811	$ 694,599
Percentage of Net Revenue		23.00%	26.00%	25.00%	27.00%
Behavioral Health Services | UK Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 136,622	$ 143,800	$ 273,472	$ 280,502
Percentage of Net Revenue		11.00%	11.00%	11.00%	11.00%
Behavioral Health Services | Other Patient Revenue and Adjustments, Net
Disaggregation Of Revenue [Line Items]
Net revenues		$ 121,135	$ 126,903	$ 244,195	$ 250,381
Percentage of Net Revenue		10.00%	10.00%	10.00%	10.00%
Behavioral Health Services | Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 106,737	$ 50,606	$ 155,819	$ 99,023
Percentage of Net Revenue		8.00%	4.00%	6.00%	4.00%
Other
Disaggregation Of Revenue [Line Items]
Net revenues		$ 3,125	$ 3,218	$ 5,634	$ 6,382
Other | Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 3,125	$ 3,218	$ 5,634	$ 6,382
[1]	Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $136 million and $144 million for the three-month periods ended June 30, 2020 and 2019, respectively, and approximately $273 million and $281 million for the six-month periods ended June 30, 2020 and 2019, respectively.  Total assets at our U.K. behavioral health care facilities were approximately $1.192 billion and $1.217 billion as of June 30, 2020 and 2019, respectively.

Schedule of Disaggregates Rev_2

Schedule of Disaggregates Revenue by Major Source (Parenthetical) (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Revenues		$ 2,729,754	$ 2,855,168	$ 5,559,421	$ 5,659,559
Acute Care Hospital Services
Disaggregation Of Revenue [Line Items]
Revenues		1,467,506	1,531,709	2,988,555	3,046,553
Acute Care Hospital Services | Governmental Stimulus Program
Disaggregation Of Revenue [Line Items]
Revenues		157,000		157,000
Behavioral Health Services
Disaggregation Of Revenue [Line Items]
Revenues	[1]	1,259,123	$ 1,320,241	2,565,232	$ 2,606,624
Behavioral Health Services | Governmental Stimulus Program
Disaggregation Of Revenue [Line Items]
Revenues		$ 61,000		$ 61,000
[1]	Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $136 million and $144 million for the three-month periods ended June 30, 2020 and 2019, respectively, and approximately $273 million and $281 million for the six-month periods ended June 30, 2020 and 2019, respectively.  Total assets at our U.K. behavioral health care facilities were approximately $1.192 billion and $1.217 billion as of June 30, 2020 and 2019, respectively.

Lease Accounting - Additional I

Lease Accounting - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)Hospital	Jun. 30, 2019USD ($)
Lessee Lease Description [Line Items]
Lessee, operating lease, existence of option to extend [true false]	true
Number of hospital facilities | Hospital	3
Right-of-use assets obtained in exchange for operating lease obligations	$ 37,780	$ 359,329
New Operating Leases
Lessee Lease Description [Line Items]
Right-of-use assets obtained in exchange for operating lease obligations		$ 8,900
Two Hospital Facilities
Lessee Lease Description [Line Items]
Lease Expiration Term	2021
Third Hospital Facilities
Lessee Lease Description [Line Items]
Lease Expiration Term	2026
Minimum
Lessee Lease Description [Line Items]
Initial term of real estate lease	5 years
Real estate leases option to extend lease term	5 years
Maximum
Lessee Lease Description [Line Items]
Initial term of real estate lease	10 years
Real estate leases option to extend lease term	10 years

Supplemental Cash Flow Informat

Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 56,102	$ 52,036
Operating cash flows from finance leases	966	1,108
Financing cash flows from finance leases	1,267	907
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 37,780	$ 359,329